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Abstract 
While cannabidiol (CBD) has been documented to elicit anxiolytic effects, only recently 
have studies demonstrated the anxiolytic efficacy of the aromatic monoterpene, linalool. Past 
research involving phytocannabinoid-phytocannabinoid formulations has shown that CBD may 
yield superior anxiolytic efficacy when administered alongside other cannabis compounds, with 
this phenomenon termed the “Entourage Effect” (EE); however, this EE has not been 
investigated in phytocannabinoid-terpene formulations. Furthermore, investigations involving 
intra-cranial CBD administration have shown the nucleus accumbens shell, known for affective 
processing, to be a therapeutic target of interest. Thus, using treatment interventions in 
behavioral and molecular assays, this thesis investigated the possibility of EE-potentiated 
anxiolysis within linalool-CBD formulations through olfactory and intra-NAcSh routes of 
concurrent acute administration, focusing on GABAAR and ERK signaling mechanisms 
previously shown to be mediated by linalool and CBD. Altogether, findings ultimately suggest 
that linalool-CBD formulations elicit EE-potentiated anxiolysis through GABAAR- and ERK-
dependent mechanisms capable of reversing chronic stress-induced anxiety. 
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Summary for Lay Audience 
Commonly referred to as cannabis, the plant species Cannabis sativa contains two major 
substances, cannabidiol and tetrahydrocannabinol (THC), both of which modulate emotional 
processing. Although these substances are collectively termed “phytocannabinoids”, they yield 
contrasting psycho-modulatory effects. While THC has been shown to yield psychoactive 
symptoms, CBD has been demonstrated to reverse these symptoms when co- or post-
administered, and also elicit anti-anxiety effects. Interestingly, developments in cannabis 
research have documented that when administered in conjunction, THC and CBD may yield 
greater anti-anxiety effects than those achieved alone with CBD plant extracts. This phenomenon 
of increased anti-anxiety effects following the combination of cannabis compounds has been 
termed the “Entourage Effect” (EE). Furthermore, studies demonstrated that administrations of 
these compounds into specific brain structures within a circuit known as the mesolimbocortical 
(MCL) pathway are especially effective in generating mood-altering effects. Within this MCL 
pathway, the nucleus accumbens brain structure—in particular its “shell” sub-region (NAcSh)—
has shown to be a therapeutic target of interest, given that past studies employing intra-NAcSh 
administrations of these cannabis compounds reported significant mood-altering results. 
Importantly however, combinations involving terpenes (aromatic substances) found in cannabis 
have yet to be explored despite their anxiolytic potential, highlighting an area of interest in the 
investigation of the Entourage Effect. 
Thus, this thesis sought to determine whether an EE existed in combined linalool 
(anxiolytic terpene) and CBD treatments, using olfactory and intra-NAcSh routes to respectively 
administer these compounds in rat models. Utilizing behavioral tests followed by molecular 
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analyses of biomarkers of interest, the findings of this thesis demonstrated that there exists EE-
potentiated anti-anxiety effects following concurrent administration of odorous linalool and 
intra-NAcSh CBD. In addition, through incorporation of protein modulators and models of 
chronic stress, the observed EE was found to successfully reverse chronic stress-induced anxiety 
and elicit anti-anxiety effects through specific protein modulations. Ultimately, these findings 
highlight the therapeutic potential of cannabis as a natural alternative to conventional 
medications used to treat anxiety symptoms and disorders. With safe use profiles, CBD and 
linalool may serve as an adjunct—or even replacement—for these conventional medications 
riddled with unwanted and potentially dangerous, side-effects. 
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1. Introduction 
Cannabis sativa, commonly referred to as marijuana or simply cannabis, is one of the 
most cultivated and consumed psychoactive substances in the world. According to the World 
Health Organization (WHO), there exists an estimated 147 million annual users of cannabis, 
which equates to roughly 2.5% of the world population, overshadowing the annual prevalence 
usage of other drugs such as cocaine (0.2%) and opiates (0.2%). Yielding a rich history 
consisting of both positive and negative affective experiences following its ingestion or 
inhalation, cannabis has begun to garner serious interest in the scientific field due to its medicinal 
properties and potential for pharmacotherapeutic applications (Callaway, 2004; Izzo et al, 2009; 
Pertwee, 2008).  
Currently, over 500 chemical substances and 100 phytocannabinoids have been 
successfully isolated and identified from Cannabis sativa, including cannabidiol (CBD) and Δ9-
tetrahydrocannabinol (THC). THC is the primary psychoactive compound in cannabis and is 
believed to be responsible for the negative side-effects of cannabis use, including episodes of 
anxiety, psychosis and cognitive deficits, especially following chronic adolescent exposure. In 
contrast, research into the psychotropic effects of  CBD has shown quite the opposite (D’Souza 
et al, 2005). Indeed, as the predominant non-psychotropic phytocannabinoid found within 
Cannabis sativa, clinical and pre-clinical evidence has shown that CBD may possess many 
therapeutic effects potentially applicable in the clinical setting (Crippa et al., 2018; Millar et al., 
2019). For example, considerable evidence has suggested that it may not only be effective in 
attenuating the psychoactive effects elicited by THC, but also effective alone in reducing both 
depression and anxiety symptoms in animal models (Boggs et al, 2017; Fogaça et al, 2014; 
Murkar et al, 2019). While the exact pharmacological mechanisms through which CBD produces 
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its purported therapeutic effects remain unclear, the potential for pharmacotherapeutic effects of 
CBD for a range of neuropsychiatric symptoms, including anxiety, depression and schizophrenia, 
is receiving considerable pre-clinical and clinical research focus (Campos et al, 2012; Pertwee, 
2008; Petrocellis and Marzo, 2009). 
Psychoactive effects, however, have also been discovered in a lesser studied group of 
compounds within cannabis known as the ‘terpenes’. Often referred to as essential oil 
components, terpenes are the substances found within cannabis which provide the plant with its 
distinctive aromatic profile, with at least 20,000 characterized and 200 reported to be contained 
in the plant (Russo, 2011). Commonly found terpenoids in both cannabis and other plants include 
limonene, α-pinene, β-myrcene, linalool, β-caryophyllene, nerolidol and phytol amongst others. 
Aside from their distinct aroma, these terpenes have also been documented in animal models to 
elicit a variety of physiological effects upon administration (via inhalation or ingestion), 
including anti-anxiety, analgesic and anti-convulsant effects (Elisabetsky et al., 1995; Peana et 
al., 2006; Russo, 2001). While terpene yields are often less than 1% in cannabis assays, 
individual terpenoid concentrations as small as 0.05% have been deemed to be of 
pharmacological significance in altering brain activity levels (Adams and Taylor, 2010). 
Given that the scientific field regarding cannabis is still relatively young and many 
mechanisms of action remain unclear, there exists a need to pursue further research in order to 
both examine the properties of CBD and terpenes as well as elucidate their underlying 
mechanisms. More importantly,  recent research has highlighted the potential for 
phytocannabinoid-terpenoid therapeutic interactions, dubbed the “Entourage Effect”, especially 
in regard to anti-anxiety effects (Russo, 2011). The entourage effect refers to the concept that 
specific compounds within cannabis, may functionally interact with each other (thus forming an 
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“entourage” or combined group effect) to synergize or potentiate the pharmacotherapeutic 
potential of cannabis-derived formulations—particularly in a manner whereby the novel 
combinatorial formulation achieves a superior psychotropic effect compared to either individual 
treatment administration alone. For example, do specific terpenes interact with either THC or 
CBD to modulate or potentiate there pharmacological and/or therapeutic properties? With this 
important concept in mind, the subsequent literature overview seeks to illustrate the importance 
of pursuing such alternative anti-anxiety medications and the mechanisms of action which 
underlie phytocannabinoid and monoterpene therapeutic effects, with a focus on exploring the 
potential for the presence of the Entourage Effect in co-administration of CBD and the specific 
mono-terpene, linalool. 
1.1 Overview of Anxiety and Anxiety Disorders 
1.1.1 Defining Anxiety and Anxiety Disorders 
Anxiety is an emotion experienced commonly throughout an individual’s life, often 
characterized by worried thoughts, feelings of tension and physiological changes such as 
increased blood pressure (Kazdin, 2000). The presentation of anxiety, according to the theory of 
cognitive appraisal proposed by Lazarus and Folkman (1984), often stems from threat appraisals 
generated by individuals in their perception of a stressful situation, or stressor. In responding to 
these threats, strategies such as emotion-, problem- and meaning-based coping are often utilized; 
consequently, by addressing these external stressors, internal states of anxiety which developed 
in response to stressors can be relieved. However, while stress is often acute in nature and 
subsides following removal of the originating stressor, anxiety can continue to persist even after 
the external stressor is eliminated. Furthermore, while feeling anxious or experiencing anxiety 
may be commonplace, increased severity of these emotions, such as frequency and deleterious 
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impacts to daily functioning, may be indicative of a chronic mental health disorder. 
According to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition 
(DSM-V) established by the American Psychiatric Association, a key element in the diagnosis of 
an anxiety disorder in comparison to normal states of anxiety, involves clinical presentations 
wherein the individual’s mental condition is severely impairing  their functioning in one or more 
activities of daily living; these include but are not limited to, social and occupational functioning 
across multiple settings. This key requirement is shared amongst the diagnoses of the eight 
principal anxiety disorders currently listed in the DSM-V: separation anxiety disorder, selective 
mutism, specific phobia, social anxiety disorder (social phobia), panic disorder, agoraphobia, 
generalized anxiety disorder and substance/medication-induced anxiety disorder. Unlike 
individuals experiencing anxiety whose mental condition may improve following therapeutic 
interventions and the development of effective coping strategies, many individuals diagnosed 
with anxiety disorders require specialized treatment to adequately manage their conditions and/or 
improve their long-term mental health outcomes. 
1.1.2 Prevalence of Anxiety Disorders and Implications 
 According to a recent systematic review conducted by the World Health Organization, 
the global age-standardized prevalence of any anxiety disorder (including post-traumatic stress 
disorder) is approximately 21.7%. Furthermore, findings suggest that in conflict settings, the 
prevalence of anxiety increases with age, with prevalence rates over 30% in individuals over 40 
years of age (Charlson et al., 2019). When assessing the lifetime prevalence of anxiety disorders 
based off of large population-based surveys, the prevalence rate was found to be as high as 
33.7% (Bandelow et al., 2015). These rates are alarming in light of the fact that the Anxiety and 
Depression Association of America reported that those with anxiety disorders are three-to-five 
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times more likely to require a clinical treatment and six times more likely to be hospitalized due 
to development of a co-morbid psychiatric disorder than those without anxiety disorders. Given 
these findings and coupled with the fact that the United Nations projects the global population to 
rise to 8.5 billion by 2030, there exists an urgent need to address the scaling and efficacy of 
treatments for this increasing number of individuals with mental health illnesses. 
1.1.3 Conventional Treatments for Anxiety Disorders 
The primary options for treating anxiety disorders include psychotherapy-based 
interventions (such as cognitive-behavioural therapy) and conventional anti-anxiety medications 
(including benzodiazepines, which potently modulate GABAergic transmission, and SSRIs 
which modulate serotonergic transmission). Previous research has indicated optimal health 
outcomes after undergoing individual cognitive behavioral therapy (large effect size of 1.30, 
n=93), which can range from 5 to 20 weekly sessions (30 to 60 minutes) to achieve desired 
health outcomes (Bandelow et al., 2015; National Health Service). Although Bandelow and 
authors found that medications such as benzodiazepines (ES: 2.15; n = 42) and selective 
serotonin reuptake inhibitors (ES: 2.09; n = 62) were more effective than cognitive behavioral 
therapy (CBT), the issues of potential side effects and unwanted drug interactions potentially 
outweighed the effectiveness of the treatments when considering patient safety and longevity of 
treatment effects. However, a 2-year follow-up meta-analyses demonstrated that through 93 
studies with 185 study arms, the enduring efficacy of both drug medication and CBT treatment 
persisted with relatively equal efficiency (Bandelow et al., 2018). When combined with the fact 
that relapse rates between drug treatments (8-56%) and CBT (48%) for anxiety disorders was 
relatively comparable, the distinction between treatment advantage becomes minimal. Other 
factors, such as ease of access, drug costs, as well as patient adherence, become influential 
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factors in determining treatment type pursuance and long-term efficacy (Bandelow et al., 2008; 
Donovan et al., 2010; Durham et al., 2005). 
Frontline anxiety medications such as SSRIs and benzodiazepines, despite their 
convenience advantages when compared to continual weekly sessions of psychotherapy, suffer 
from multiple drawbacks, including potential ineffectiveness and chronic side-effects, such as 
drug dependence and withdrawal. In a recent study by Kagan et al. (2020) which conducted a 3-
to-12 year follow-up after initial treatment in the child/adolescent multimodal extended long-
term study (CAMELS Trial), the 40.6% of [total] 318 patients who chose to discontinue anxiety 
medication use following the trial reported primary concerns of perceived ineffectiveness 
(31.8%) and side effects (25.5%). To compound issues further, a study conducted by Read and 
Williams (2018) found that 61% of patients (n=1431) reported experiencing at least 10 adverse 
effects, including blunting of affect (71%), sexual dysfunction (66%), suicidality (50%), 
withdrawal symptoms (59%) and addiction concerns (40%). The latter two adverse effects of 
withdrawal and addiction are of vital concern when addressing the tranquilizer-class anxiety 
medications, the benzodiazepine family. Despite their acute efficacy, studies suggest that usage 
of over four months, higher dosages, immediate drug cessation and utilization of short-acting 
benzodiazepines such as alprazolam, can result in the development of serious withdrawal 
syndromes (Owen and Tyrer, 1983). Reported withdrawal symptoms include epileptic seizures, 
tachycardia, gastrointestinal dysfunction, drug tolerance and locomotor abnormalities, often 
resulting in a transition to higher and higher doses of benzodiazepines (Franck et al., 2004). 
Long-term problems with cognitive functioning among patients even after six months following 
drug cessation was reported by Barker (2004). In summary, these multiple issues of both short 
and long-term side-effects associated with most current anti-anxiety medications, raises 
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substantial concerns about their viability as the primary go-to treatment of choice for anxiety 
treatments. More importantly, they underscore the importance in finding alternative 
pharmacotherapies for the treatment of anxiety disorders that display fewer side-effects, better 
patient tolerance and long-term safety profiles.  
1.2 The Mesocorticolimbic Pathway 
Central to an understanding of the mechanisms underlying the presentation of anxiety 
symptoms is an investigation of the mesocorticolimbic (MCL) pathway—comprised of the 
mesocortical and mesolimbic neural pathways, it is critically involved in a host of cognitive and 
affective functions including learning, emotion, memory and motivated behaviours related to 
reward learning (Helbing et al., 2016; Yamaguchi et al., 2011). It includes the dopaminergic 
(A10) neurons which project from the ventral tegmental area (VTA) to the prefrontal cortex 
(PFC), nucleus accumbens (NAc) and olfactory tubercle, with the combination of the latter two 
structures referred to as the ventral striatum (Ikemoto, 2010). Notably however, the mesolimbic 
pathway is reciprocal in nature, with GABAergic projections from the nucleus accumbens 
extending into regions such as the VTA and regulating its activity in turn (Yang et al., 2018). 
While the mesolimbic pathway consists of the VTA and ventral striatum, its impact on cognitive 
functioning revolves around connections with other brain structures. Connections to the 
amygdala and hippocampus ultimately allow for the development of fear learning and memory 
formation, while connections with the prefrontal cortex and anterior cingulate cortex allow for 
mediation of emotional regulation and executive functioning (Everitt and Robins, 2005). 
1.2.1 Nucleus Accumbens 
 The Nucleus Accumbens (NAc) is a site of convergence for many excitatory afferent 
connections including the VTA, cerebral cortex and thalamus, allowing for subsequent 
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regulation of behavioural responses towards reward and conditioned learning and memory 
(Nicola et al, 2000; Wise, 2004; Zahm, 2000). Structurally, the NAc is comprised of two major 
divisions: the core (NAcc) and the shell (NAcSh). Both divisions consist of mostly medium 
spiny neurons (MSN) which have been found to have relatively low baseline firing rates, 
suggesting these neurons are primarily GABAergic in nature (Castro and Bruchas, 2019). Highly 
regulated through dopamine innervation, the MSNs within the NAc have been identified to 
contain multiple dopamine receptor variations including D1 and D2 subtypes. These subtypes 
have been found to partially delineate NAc efferent projections referred as direct (primarily D1; 
targets: substantia nigra and VTA) or indirect (primarily D2; targets: pallidal and hypothalamic 
structures) pathways (Castro and Bruchas, 2019).  
 On a systems-level, the NAc has also been implicated by studies as being critically 
important brain region in the management of anxiety-related behaviors (Kalin et al., 2005; Lago 
et al., 2017; Levita et al., 2012). As documented by Levita et al (2012) and Lago et al. (2017), 
the involvement of the NAc in modulating motivation may not only be limited to risk/reward 
responses, but also the motivation to avoid danger; as a result, aberrant NAc activity states result 
in impaired risk avoidance management that underlie the maladaptive avoidance behaviors in the 
vast majority of anxiety disorders. These interpretations compliment the findings made by Kalin 
et al. (2005) who utilized PET scanning and demonstrated in rhesus monkey models that 
increased NAc metabolic activity is positively correlated with excessive freezing time in the 
human intruder paradigm—effectively emphasizing the importance of the NAc in modulating 
perceived anxiety.  
Furthermore, developments in the field of natural medications have yielded interesting 
findings implicating the NAc as a region of interest for therapeutic interventions (Bhattacharyya 
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et al., 2010). Through the use of functional mangetic resonance imaging (fMRI), Bhattacharyya 
and authors showed that oral administrations of the phytocannabinoid, cannabidiol (derived from 
the plant species Cannabis sativa), were able to reverse aberrant NAc activity and psychotic 
symptoms induced by exposure to the psychoactive phytocannabinoid, Δ-9-
Tetrahydrocannabinol. Given that abnormal NAc activity has been linked to increased anxiety 
symptoms (Kalin et al., 2005) and that severe anxiety can lead to the presentation of psychotic 
symptoms, this collection of aforementioned studies highlights the therapeutic potential for the 
development of treatments targeting NAc activity in the management of mood/anxiety disorders. 
1.2.2 Prefrontal Cortex 
 Many studies have demonstrated that the prefrontal cortex (PFC) is instrumental in 
modulating neuronal activity underlying anxiety and depression (Hare and Duman., 2020; 
Ironside et al., 2019). Comprised of numerous subdivisions including the prelimbic, ventral 
orbital, ventrolateral orbital and dorsolateral orbital regions, the PFC sends glutamatergic and 
GABAergic neurons to associated brain regions to elicit downstream effects (Bedwell et al., 
2015; Lee et al., 2014; Wanchoo et al., 2009). While the exact mechanisms of action through 
which the PFC exerts its systems-level effects is still unclear, the PFC has been found to be 
directly involved in inhibiting aversive memories developed in fear conditioning paradigms, with 
inactivation measures such as lesions of the PFC leading to decreased extinction while PFC 
electrical stimulation led to increased extinction of conditioned responses (Ledoux, 2000; 
Maroun et al., 2012; Morgan et al., 1993; Muller et al., 1997). 
 While the PFC has been implicated in the processing of emotions, it is arguably best 
known for its role in cognitive functioning and executive decision-making. A primary area of 
focus has been its direct and indirect involvement in establishing and maintaining working 
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memory, as well as its influence on the motor cortices in carrying out locomotor activity 
(Funahashi, 2017; Lara and Wallis, 2015; Schulz et al., 2019). In light of these various integral 
roles that the PFC is involved in, as well as the fact that it has been implicated in emotional 
processing, the PFC presents a significant target of interest in which anxiety—and anxiety-
related cognitive changes—can be studied using electrophysiology or drug treatment protocols to 
elucidate potential mechanisms and intra- or inter-PFC functional connections correlating with 
observed behavioral phenomena. In fact, recent research in our laboratory has shown that the 
cannabidiol can potently modulate cognitive and affective functions in the PFC (Szkudlarek et 
al., 2019). Specifically, Szkudlarek and authors had demonstrated that acute treatment of intra-
cranial CBD infusions into the PFC region was capable in reversing symptoms of cognitive 
changes that stemmed from aberrant PFC states and THC administration via 5-HT1AR signaling 
mechanisms, highlighting the potential for therapeutic interventions targeting the PFC region in 
the management of mood/anxiety disorders. 
1.2.3 Functional Connections between the PFC, NAc and Associated Brain Regions 
While the two mesocorticolimbic brain regions of the NAc and PFC have been shown to 
play important roles in affective processing as described in previous sections, a full 
understanding of the mechanistic intricacies of the mesocorticolimbic pathway involves the 
study of the relationship between PFC and NAc—more specifically, the various connections 
between the two brain regions which modulate each other’s activity states. The NAc in particular 
has been found to receive both glutamatergic and GABAergic projections from the PFC (Lee et 
al., 2014; Russo and Nestler, 2013; Torregrossa et al., 2008; Wanchoo et al., 2009). While 
increased activity from PFC glutamatergic projections to the NAc was determined to be 
antidepressant in nature (Russo and Nestler, 2013), optogenic stimulation of GABAergic 
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projections from the PFC to the NAc was found to result in increased avoidance behavior by 
rodent subjects (Lee et al., 2014). Conversely, the NAc is able to indirectly modulate the activity 
of the PFC through efferent GABAergic projections to the VTA, which in turn regulate 
dopaminergic release from the VTA to the PFC, effectively modulating PFC neuronal activity 
(Buchta et al., 2017; Ellwood et al., 2017; Norris et al., 2016; Yang et al., 2018). Collectively, 
these studies demonstrate the integrative nature in which the NAc and PFC function as a system 
rather than standalone structures on a molecular level within the mesolimbocortical pathway. 
As mentioned above, associated brain structures such as the VTA play an important role 
in facilitating affective processing within the MCL pathway. Interestingly, in addition to 
projections to the PFC, the VTA has been documented to reciprocally modulate the NAc through 
VTA-NAc dopaminergic projections (Groenewegen and Russchen, 1984; Heimer et al, 1991; 
Nauta et al, 1978; Sesack et al., 2009; Somogyi et al, 1981; Zahm and Heimer, 1993). This is 
particularly important to note as behavioral studies have documented impaired VTA-NAc 
circuitry to be responsible for anxiety-related social behavior dysfunction and avoidance (Russo 
and Nestler, 2013; Van der Kooij et al., 2018), suggesting that the VTA is capable of modulating 
both PFC and NAc activity states during affective processing. 
Furthermore, within the mesolimbocortical pathway, the discovery of PFC-amygdala 
connections has led to studies documenting the important role of the PFC in regulating amygdala 
activity, with complete extinction of conditioned aversive responses being achieved in 
conjunction with increased fMRI activity of the PFC region and decreased activity in the 
amygdala (Ironside et al., 2019; Pitman et al., 2012). In addition to these findings highlighting 
brain activity alteration in response to PFC activation/inactivation, it is worth noting that 
individuals diagnosed with depression and those with an anxiety disorder (including PTSD) have 
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been found to exhibit hyperactive amygdala activity that is hypothesized to be due to reduced 
inhibition from the PFC (Etkin et al., 2010; Hamilton et al., 2012; Maroun et al., 2012; Rauch et 
al., 2000). Interestingly, while this top-down regulation from the PFC to amygdala predominates 
the literature surrounding the two regions’ connections, GABAergic projections from the 
amygdala to the PFC presents the notion that the PFC-amygdala connections are reciprocal, 
rather than unidirectional in nature—adding an element of complexity to determining the 
individual functionality of each region (Seo et al., 2016). 
  Taken together, these studies documenting the various functional connections between 
these mesolimbocortical brain regions suggests clearly that not only do the PFC and NAc play a 
role in affective processing, but that these regions are influenced by associated brain structures 
such as the VTA and amygdala—emphasizing the fact that the affective processing abilities of 
the PFC and NAc are not only modulated by one another, but also by other brain regions within 
the MCL circuit that should be considered within a comprehensive analysis of MCL affective 
processing. 
1.2.4 The Role of the Mesocortiolimbic Pathway and Receptor Targets in Anxiety Disorders 
Due to its integral role in emotion and cognitive processing as previously described, the 
mesocorticolimbic (MCL) pathway has been implicated in many studies not only assessing 
reward and motivation learning, but also anxiety disorders as well. A study conducted by 
Burkhouse et al. (2020) found that the NAc played a critical role during treatment recovery from 
anxiety disorders, as greater bilateral NAc volumes correlated with significantly greater 
reductions in anxiety symptoms pre-to-post SSRI and CBT treatment. In conjunction with 
findings that suggest NAc plays a key role in the communicative circuit between the amygdala 
and the prefrontal cortex (Mannella et al., 2013), growing evidence suggests NAc may be a key 
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target in anxiety disorder treatment and in the broader MCL pathway. 
As a vital component of the cortical aspect of the MCL pathway, the PFC has been 
implicated in a host of cognitive and affective functioning roles, including its top-down 
inhibition of the amygdala by the PFC, yielding in turn a distinct profile of increased PFC 
regulatory control being linked to decreases in perceived anxiety levels as mentioned earlier 
(Ledoux, 2000; Maroun et al., 2012; Morgan et al., 1993; Muller et al., 1997). When considered 
in conjunction with the findings that decreased PFC volumes have been correlated to increased 
measures of both anxiety and depression (Madonna et al., 2019; Mohlman et al., 2009) and that 
patients with anxiety and/or depressive disorders have been found to possess circuit 
abnormalities in amygdala and hippocampal regions—two associated brain regions within the 
mesocorticolimbic pathway essential in fear memory acquisition and recall—the PFC presents 
itself as a viable target in the treatment of anxiety, depression or comorbid diagnoses of these 
two mood disorders (Etkin et al., 2010; Godsil, 2013; Hamilton et al., 2012; Maroun et al., 2012; 
Rauch et al., 2000).  
Expanding upon the VTA-NAc circuitry analysis discussed in section 1.2.3, recent 
studies examining the VTA have demonstrated the significance of its activity in the presentation 
of anxiety symptoms. A study conducted by Cha et al. (2014) utilized fMRI to measure the brain 
activity of participants while undergoing fear generalization tasks, with findings indicating that 
participants with generalized anxiety disorder (GAD) exhibited heightened VTA activity 
compared to non-GAD subjects in response to generalized stimuli. VTA hyperactivity was also 
shown to correlate to manic states in mouse models, characterized by increased dopaminergic 
activity and resulting locomotor abnormalities (Coque et al., 2011). When considering the 
DAergic projections from the VTA to the NAc as well as its connections to cortical regions, the 
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VTA ultimately presents a vital area of interest along with the NAc in the management of 
anxiety disorders. 
Correlations between behavioral and molecular analyses highlight GABA and 5-HT 
receptors and their associated downstream molecular pathways, as being essential targets when 
assessing models of anxiety and anxiety symptoms. Using proton magnetic resonance 
spectroscopy, Strasser et al. (2019) had demonstrated that there existed a significant negative 
correlation between subjects’ perceived situational stress and NAc GABA levels. This data 
signifying the importance of NAc GABA levels in regulating anxiety is supported by Lopes et al. 
(2012), who found that GABA-inhibition within the NAcSh increased anxiety symptoms in the 
context of rodent feeding behaviour. In a similar manner, increasing evidence points towards 
decreased intra-PFC GABA levels contributing towards the establishment and maintenance of 
anxiety and depression disorders (Ghosal et al., 2017), suggesting that internal imbalances in 
inhibitory control within these brain regions can lead to significant systems-level mood 
dysfunction. Interestingly, the application of GABAAR antagonists in the VTA has been found to 
be crucial in reversing drug-induced behavioral changes following their microinfusion 
administrations into the NAcSh and VTA (Blacktop et al, 2016; Norris et al, 2016)—
highlighting the importance of GABAergic transmission between the NAcSh and VTA as well as 
within VTA local circuitry. Overall, these studies suggest that both GABA levels and 
GABAergic transmission within the mesocorticolimbic pathway are vital in the management of 
anxiety, as indicative of the effectiveness of benzodiazepine as a frontline anxiety medication. 
Existing evidence suggests that dysregulation of serotonergic transmission also plays a 
significant role in the development of anxiety disorders, with decreases in 5-HT levels and 
serotonergic transmission being associated with increased anxiety (Gartside et al., 1995). In 
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particular, abnormal 5-HT1AR activity has been implicated in both the development and 
treatment (SSRIs) of anxiety disorders (Akimova et al., 2009; Gordon and Hen, 2004; Lesch and 
Gutknecht, 2004; Strobel et al., 2003). Within the PFC, 5-HT1ARs have been found located on 
pyramidal glutamatergic neurons as well as interneurons that act on these pyramidal cells; 
analysis conducted by Albert et al. (2014) have demonstrated anxiety symptoms to present 
during low and high levels of 5-HT, presenting an interesting notion of non-directional 
imbalance of 5-HT levels being the etiology of intra-PFC mood dysfunction. In addition to the 
presence of HT1AR and its autoreceptor activity within the PFC and raphe nuclei (Garcia-Garcia 
et al., 2014), HT1AR have been found localized on GABAergic interneurons within the NAcSh 
(Van Bockstaele et al., 1996). This in turn suggests that serotonergic afferent projections to the 
NAcSh may directly inhibit these interneurons, allowing for downstream increased activity of 
striatal projections and modulation of anxiety-processing brain structures.  
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1.2.5 Overview of Notable Molecular Biomarkers in Anxiety Disorders 
In terms of downstream molecular signaling pathways associated with anxiety disorders, 
abnormal levels of intracellular biomarkers such as GSK3β, Akt, ERK and JNK proteins have 
been associated with anxiety symptoms and mood disorders (Crofton et al., 2017; Engeli et al., 
2014; Jope et al., 2006; Willock et al., 2016). While the activity of these proteins have been 
correlated with presentations of anxiety symptoms which may appear phenotypically similar, the 
generation of these symptoms through the regulation of specific signaling pathways and 
downstream effectors documented in the literature is relatively unique between the proteins.   
GSK3β, otherwise known as glycogen synthase kinase-3β, is a constitutively active 
protein whose downregulation has been shown to be correlated with potential anxiolytic effects 
(Crofton et al., 2017; Mines et al., 2010). Specifically, assessing the function of GSK3β within 
the NAcSh, Crofton et al. (2017) demonstrated that GSK3β-knockdown  in rat models 
effectively decreased anxiety-like behavior through a potential suppressing mechanism on 
tonally active interneurons (TANs). In another study, Mines et al. (2010) found that inhibition of 
GSK3 in Fmr1 knockout mice decreased displays of anxiety during social interaction. As a 
downstream target of both the Wnt and PI3K-Akt pathways, GSK-3β is readily inhibited through 
phosphorylation of its Serine-9 residue within the N-terminus domain (Sani et al., 2012). 
 Akt, often referred to as Protein Kinase B, is a member of the PI3K-Akt pathway 
involved in various cell activities including survival and proliferation (Qiao et al., 2018). 
Phosphorylation at the Serine-473 and Threonine-308 residues in the activation loop of the 
enzyme activates Akt, resulting in the activation of many downstream targets including the 
inhibition of GSK3β (Bellacosa et al., 1998; Cross et al., 1995). Knockdown and polymorphism 
analysis of Akt within animal and human subjects demonstrated that alterations of Akt ultimately 
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resulted in increased susceptibility to chronic stress as well as heightened displays of trait 
anxiety, suggesting that Akt signaling plays a critical role in mood/anxiety regulation (Engeli et 
al., 2014; Willock et al., 2016). 
 Extracellular signal-regulated kinase (ERK) is a member of the mitogen-activated protein 
kinase (MAPK) pathway responsible for a host of cellular roles, including but not limited to 
mitogen signaling in cell cycle progression and integration of stress signals (Einat et al., 2003; 
Zamora-Martinez et al., 2014). Often activated in response to cell stress, increased concentration 
of phosphorylated ERK (p-ERK) has been associated with increased symptoms of anxiety and 
depression, as well as overall mood dysregulation in various brain regions including the frontal 
cortex and hippocampus (Ailing et al., 2008; Einat et al., 2003; Hudson et al., 2019).   
 JNK, also referred to as c-Jun N-terminal kinase, is also a member of the MAPK family 
pathway along with ERK; as such, its phosphorylated activation occurs primarily in response to 
perceived cell stress (Zeke et al., 2016). While the primary active isoform, JNK1, is known for 
its role in regulating neuronal differentiation and maturation, studies have also implicated JNK1 
in facilitating the development of symptoms reflective of anxious and depressive states (Hollos 
et al., 2018; Mohammad et al., 2018). Interestingly, a proposed mechanism through which JNK1 
elicits its effects within the hippocampus is through the prioritization of immature granule cell 
neurogenesis. These immature cells have been observed to negatively regulate mature dentate 
granule cell populations through recruitment of synapsing GABAergic inhibitory neurons, 
resulting in overall decreased hippocampal neuronal activity and abnormal communication with 
connected brain regions (Marín-Burgin et al., 2012). 
 While individual analyses of these protein biomarkers have yielded promise in providing 
potential mechanisms to address in regard to anxiety disorder and treatment, it should be noted 
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that these proteins ultimately work in conjunction with one another through both direct 
interactions (e.g. the inhibition of GSK3β by Akt) as well as indirect downstream targets. 
Furthermore, depending on the brain region being influenced, the resulting activation or 
inactivation of these enzymes may yield varying behavioral outcomes. 
1.3 Cannabis: An Alternative Treatment for Anxiety Disorders 
1.3.1 Effects of Cannabis on Mental Health 
 Despite recorded usage as a medicinal plant for the past millennia, the effects and 
underlying mechanisms of cannabis have still yet to be fully uncovered (Mechoulam, 1986; 
Russo, 2007; 2008). Indeed, while cannabis’s effects have been primarily attributed to key 
natural constituents such as tetrohydrocannabinol (THC) (Gaoni and Mechoulam, 1966), 
naturally occurring endocannabinoids such as anandamide (AEA) (Devane et al., 1992) and 2-
arachidonoylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al., 1995), as well as 
cannabidiol (CBD) and other such phytocannabinoids, the overall physiological effects that the 
plant Cannabis sativa yields as a whole has yet to be conclusively defined. 
 Nonetheless, clinical and pre-clinical cannabis research has demonstrated the potential 
therapeutic use of cannabinoid formulations including administration of plant extracts in the 
treatment of movement disorders, psychiatric disorders, Alzheimers disease, epilepsy, pain and 
multiple sclerosis (Montero-Olease et al., 2020). A defining milestone in the development of 
cannabis-related therapeutic formulations include the United Kingdom’s approval of Nabiximols 
(CBD-THC extract) in treating pain and spasticity in multiple sclerosis following a clinical study 
conducted by Novotna et al. (2011). Although whole-plant extracts have yet to be approved by 
North American regulatory agencies in the treatment of health conditions, cannabis-derived and 
related products such as the FDA-approved drugs Epidiolex (purified CBD extract treating 
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syndrome-specific seizures) and Dronabinol (synthetic THC used as an appetite stimulant, 
antiemetic and sleep apnea remedy) highlight the therapeutic potential of cannabis-related 
products. 
1.3.2 Properties and Mechanisms of Action of Cannabidiol 
Cannabidiol is a major phytocannabinoid within Cannabis sativa whose psychotropic 
effects have largely been attributed to its regulatory role in the reduction of psychoactive 
symptoms associated with THC. Within the endocannabinoid system, it has been demonstrated 
that while cannabidiol possesses low affinity towards the endocannabinoid receptors CB1 and 
CB2 which THC interacts with, CBD is capable of antagonizing the effects of CB1 and CB2 
receptor agonists (Pertwee et al., 2002; Thomas et al., 2007). In addition, more recent studies 
have suggested that CBD can act as a negative allosteric modulator for both CB receptors, 
supporting the role of CBD as an inverse agonist for both THC and 2-AG receptor interactions 
within the endocannabinoid system (Laprairie et al., 2015; Martínez-Pinilla et al., 2017; Morales 
et al., 2016). Furthermore, a pre-clinical study by Hudson et al. (2019) discovered a potential 
mechanism of action for THC/CBD interactions, demonstrating that increased anxiety-salience 
observed following intra-ventral hippocampal infusions of THC was due to modulation of 
extracellular signal-regulated kinase phosphorylation (p-ERK1/2). Subsequently, CBD-THC 
coadministrations were found to reverse these observed changes through downregulation of p-
ERK1/2 activity, providing further evidence for this pathway mechanism. Interestingly however, 
CBD has also been found to indirectly augment CB receptor activity, potentiating the effects of 
the CB receptor agonist anandamide (AEA) through its competitive interference in transport 
protein binding, with clinical trials suggesting the subsequent elevation of AEA levels to be 
inversely correlated with the presentation of psychotic symptoms in schizophrenia or 
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schizophreniform patients (Leweke et al., 2012). 
Aside from endocannabinoid receptors, CBD acts on several anxiety-related receptor 
targets within the mesolimbic pathway, including 5-HT and GABA receptors. The effect of CBD 
on 5-HT1A receptor activation in particular, is well documented, with both behavioral and 
molecular studies demonstrating its role as an agonist at this subtype (Linge et al., 2016; Norris 
et al., 2016; Pelz et al., 2017; Resstel et al., 2009; Russo et al., 2005). In terms of the mesolimbic 
pathway, Norris et al. (2016) reported that administration of a 5-HT1A antagonist, NAD299, into 
the NAcSh was effective in reversing the anxiolytic effects elicited by CBD within an olfactory 
fear memory paradigm—suggesting 5-HT1A auto-receptor activation to be potentially integral to 
the regulation of NAcSh GABA neurons and overall fear memory formation. 
 The interaction between CBD and GABA receptors is rather distinct between the two 
receptor subtypes, GABAA and GABAB. While current evidence suggests that CBD does not act 
through GABAB receptor activation (Lopes et al., 2012; Straiker et al., 2018), there exists 
multiple studies which demonstrate its effects on the GABAA receptor, where can act as a 
positive allosteric modulator (Bakas et al., 2017; Lopes et al., 2012; Morano et al., 2016; Ruffolo 
et al., 2018). In addition, given that both in-vitro and in-vivo studies (Mallet et al., 2005; Tepper 
et al., 2008) have shown GABAAR activation to inhibit GABA interneurons within the ventral 
striatum—and more importantly, the subsequent increase in firing activity by NAc projection 
neurons following such interneuron inhibition—there may exist a potential GABAAR-mediated 
pathway of modulation in regards to the ability of the NAcSh to inhibit downstream VTA 
DAergic activity and consequently modulate emotional states. 
These mechanisms of action may shed light on the reported therapeutic properties of 
cannabidiol, including anticonvulsive, anxiolytic, antipsychotic, anti-inflammatory and anti-
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nausea effects (Mechoulam et al., 2002). Furthermore, despite its relatively poor bioavailability 
through oral ingestion, pharmacological significance for both CBD and its metabolites has been 
found in-vivo (Ujváry et al., 2016); in fact, Bergamaschi et al. (2011) demonstrated that a single 
600mg oral dose of CBD was effective in significantly reducing anxiety symptoms of social 
anxiety disorder (SAD) patients. With consideration of its relatively safe profile as a non-
psychoactive phytocannabinoid, CBD may ultimately constitute a natural alternative in place of 
or assisting conventional medications in the treatment of neuropsychiatric conditions, especially 
anxiety disorders, given CBD’s ability to influence the activity of 5-HT and GABAA receptors 
that play a key role in the pathophysiology of such disorders. 
1.3.3 Properties and Mechanisms of Action of the Mono-Terpene, Linalool 
Linalool is an odorous, acyclic monoterpene found within many plants including 
Lavandula angustifolia (Lavender) and Cannabis sativa (Milanos et al., 2017). As a component 
of various essential oils, the use of linalool includes not only its incorporation in the perfume 
industry but also in the treatment of various pathological conditions. For example, numerous 
studies have reported that exposure to linalool can produce various effects, including but not 
limited to cardiovascular effects (Anjos et al., 2013), anti-inflammatory effects (Huo et al., 2013) 
and anxiolytic effects (Bradley et al., 2007; Harada et al., 2018; Linck et al., 2010).   
Despite differing modes of administration (intraperitoneal, oral, odorous), various studies 
have proposed that the underlying mechanisms of action for the physiological effects of linalool 
and Lavandula angustifolia (which primarily consists of linalool and linalool metabolites) 
involve the activation of GABAA and 5-HT1A receptors (Harada et al., 2018; Kessler et al., 2012, 
2014; Malcolm and Tallian, 2018; Milanos et al., 2017), as well as competitive inhibition of 
NMDA receptors (Brum et al., 2001; Elisabetsky et al., 1995, 1999). In addition, in-vitro studies 
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have demonstrated that linalool administration to SH-SY5Y neuronal cells significantly 
decreases expression of adenylate cyclase I, p-ERK and PKA, all of which are associated with 
anxiety-related phenotypes, highlighting another potential mechanism manner in which linalool 
may exert its psychotropic effects (Caputo et al., 2016; 2017; 2018). 
Of particular interest for clinical applications is the non-invasive, olfactory route of 
linalool administration. While a major aspect of the odorous effects of linalool were originally 
thought to involve the inhalation and subsequent dissolving of linalool into the bloodstream, 
Harada et al. (2018) have shown that linalool exposure in anosmic mouse models produces 
anxiolytic effects via functional olfactory pathways. Given that the olfactory nervous system 
connects to brain regions associated with memory, emotions and arousal such as the entorhinal 
cortex and amygdala (Christen-Zaech et al., 2003), activation of these systems presents a 
plausible explanation for anxiety symptom reduction following olfactory linalool administration. 
Similar to CBD, given the relative safe profile of linalool and its metabolites (Malcolm et 
al., 2018) as well as its documented anxiolytic effects exhibited in both animal and human 
studies following non-invasive odor administration (Harada et al., 2018; Linck et al., 2010; 
Takahashi et al., 2011; Zhang et al., 2016), there is potential usage for linalool as an anxiolytic 
compound or in co-administration with conventional anti-anxiety medications or anxiolytic 
cannabinoids, such as CBD. 
1.3.4 The Entourage Effect 
 The Entourage Effect refers to the proposed mechanism by which combinations of 
separate phytocannabinoid extracts might yield psychoactive effects that are more potent than 
their individual administration (Ben-Shabat et al., 1998; Mechoulam et al., 1999; Russo, 2011). 
Wagner and Ulrich-Merzenich (2009) have proposed that the potential mechanisms through 
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which the Entourage Effect might be observed include multi-target receptor effects, increased 
pharmacokinetic efficiency, improved bactericidal effects as well as modulation of adverse 
events—with the latter being well established in the case of CBD’s ability to attenuate THC-
induced psychosis (Davies and Bhattacharyya, 2019; Hahn, 2018). 
 Moreover, studies have demonstrated that whole-plant extracts of Cannabis sativa have 
yielded greater therapeutic effectiveness in comparison to pure component administrations. For 
example, Johnson et al. (2010) observed in a randomized controlled trial of advanced cancer 
patients that while treatment with pure-THC extract did not yield significant anti-nociceptive 
effects compared to placebo, patients taking CBD:THC combined extracts reported significantly 
less pain compared to placebo-treated patients. In the context of animal studies, Gallily et al. 
(2015) reported that while increasing dosage administrations of pure-CBD extracts in mouse 
models yielded a biphasic effect on the mediation of inflammation, the dose-response curve 
observed following whole-plant extract treatment resulted in a starkly linear correlation between 
increased dosage and decreased presence of inflammatory cytokines. 
 While the therapeutic effects of linalool are well documented as previously described, 
research specifically examining the existence of a potential Entourage Effect involving linalool-
cannabinoid combinations is relatively scarce. Interestingly however, Takahashi et al. (2011) 
discovered that there existed significant differences in anxiolytic efficiencies between Lavandula 
plant species depending on their percentage composition of linalool (LO) and linalool acetate 
(LA). While correlational analysis indicates lack of significant correlation between linalool vs. 
anxiolysis (r = +0.54) and linalool acetate vs. anxiolysis (r = +0.72), there was a significant 
correlation (P < 0.05) between combined LO + LA odorous treatment and anxiolytic efficiency 
(r = +0.82). This study suggests the mechanistic potential for interaction dynamics between 
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linalool and other cannabis compounds in achieving anxiolytic outcomes. 
 As it currently stands in the literature surrounding cannabis research, there exists a lack 
of studies documenting the potential for Entourage Effects between the monoterpenes and 
phytocannabinoids (Russo, 2011). However, given previously described similarities in both 
receptor targets (GABAAR, 5-HT1AR, p-ERK downregulation), common modulation of neuronal 
pathways and anxiolytic outcomes between linalool and CBD, there exists an interesting 
possibility for the existence of an Entourage Effect between the two compounds. This 
exploration forms the foundation for my research project and thesis. 
1.4 Research Aims and Hypothesis 
 The overarching hypothesis of my thesis is that combinations of CBD with linalool yield 
greater reductions in anxiety-related behaviors and anxiety-related molecular biomarkers 
compared to individual administrations of either treatment due to an Entourage Effect between 
the two compounds. 
 In have addressed this general research question with the following specific 
experimental aims: 
 Aim 1: Determine if CBD-linalool co-administration in the NAcSh on anxiolytic 
measures of spatial cognitive functioning, emotional memory formation and processing within 
the baseline cohort exhibit an Entourage Effect by potentiating the behavioural anti-anxiety 
effects of either compound alone. 
 Aim 2: Characterize the pharmacological mechanisms associated with any potential 
linalool-CBD entourage effects by determining the potential roles of the anxiety-related 
biomarkers GABAA or ERK-1-2 signalling pathways in these effects. Subsequently, characterize 
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the localized molecular signaling effects of CBD, linalool or their combination, on anxiolytic 
actions directly in the NAcSh in baseline cohorts. 
Aim 3: Determine whether the anxiolytic effects elicited by linalool-CBD combinations 
are able to reverse anxiety symptoms induced by exposure to chronic unpredictable stress within 
the chronic stress cohort. 
2. Methods 
2.1 Animals and Housing 
Adult male Sprague-Dawley rats (300-400 grams) were acquired from Charles River 
Laboratories (Quebec, Canada) and used in accordance with guidelines outlined by the Canadian 
Council for Animal Care (CCAC) and University of Western Ontario Animal Care Committee 
(AUS protocol 2018-053). Upon arrival, rats were paired and housed together under controlled 
conditions (constant temperature and humidity, food and water provided ad libitum, 12-hour 
light/dark cycle) monitored by both ACVS and laboratory technicians in the designated animal 
care facility at Western University. Rat housing specifications include a plexiglass rectangular 
box filled with approved corn bedding and environmentally enriched objects (such as wood 
chewing blocks, and paper nesting material). 
 
2.2 Surgical Procedures 
Surgical procedures for adult male Sprague-Dawley rats were initiated after at least 7 
days following their arrival to the animal care facility at Western University. Rat subjects 
designated for surgery were anesthetized with a 2 : 1 mixture ratio of Ketamine (80 mg/kg; 
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Vetoquinol) and Xylazine (6 mg/kg; Bayer) via intraperitoneal injection. Following confirmation 
of the lack of a pain reflex response, subjects were then treated with meloxicam (1 mg/kg) to 
further decrease any pain perception as well as inflammation; in addition, a second dosage was 
administered during the first day post-surgery. Rats were positioned in stereotaxic apparatus for 
cannula implantation, with a warm heat pad positioned below a disposable urine pad to maintain 
constant body temperature; to this end, the subject’s temperature was taken both pre- and post-
surgery. Following surgical preparation, eight-millimeter stainless steel guide cannulas (22 G; 
Plastics1) were implanted into the NAcSh bilaterally at a 12° angle using these stereotaxic 
coordinate positions at a 12° angle (mm from bregma): anterior-posterior (AP) ± 1.8, lateral 
(LAT) ± 2.6, and ventral (V) – 7.4 from the subject’s dural surface. All coordinates were 
acquired from the Rat Brain Atlas created by Paxinos and Watson (2005). Guide cannulas were then 
secured in place through the use of miniature screws attached to the skull and dental acrylic cement. 
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2.3 Drug Preparation and Administration 
Linalool (97%; Acros Organics), CBD, EPA (eicosapentanoic acid, ERK activator) and 
Flumazenil (Tocris) were utilized in this study.  Regarding intra-cranial drug infusions, vehicle 
solutions comprised of dimethyl sulfoxide (DMSO), cremophor and 0.9% pH 7.4 saline (1:1:18). 
CBD-only, EPA-only and Flumazenil-only drug solutions were created from dissolving the 
respective drugs in the DMSO-Cremomophor-Saline solvent (referred to in brief as the “PBS 
solution”), with a mixture ratio of 1:1:18 to 5:5:30. Combination administrations, namely the 
CBD-EPA and CBD-Flumazenil treatment mixtures, were created using the 1:1:18 and 5:5:30 
ratio compositions respectively. Nitrogen gas was used to evaporate the ethanol solvent from the 
original EPA stock solution. Target concentrations of drugs within each mixture were as follows: 
5 ng/0.5µL CBD (sub-threshold dosage; Norris et al., 2016), 1 mM EPA (effective dosage in 
attenuating CBD-THC anxiolytic effects; Hudson et al., 2019) 5 μg/µL flumazenil (effective 
dose from an aggregate of studies; Da Cunha et al., 1999, Dos Reis and Canto-de-Souza, 2008, 
Herzog et al., 1996, Jardim et al., 2001). 
To prepare for odorous drug administration, the day prior to beginning behavioral testing, 
rat subjects were placed within a transparent, rectangular plexiglass cage with a filter top (to 
prevent odours from entering or leaving the cage) and four spice jars (one in each corner, secured 
by Velcro adhesive). The spice jars each contained a small weigh boat which contained distilled 
water (2000 μL); this cage apparatus would serve as the medium for the odorous drug delivery. 
Rat subjects were allowed to habituate to this novel environment for 30 minutes before being 
placed back into their housing cages. On test day, subjects were placed within the same odor-
exposure box for a 30-minute exposure session; however, based on their treatment group 
designations, they would be exposed to either distilled water (2000 μL) or linalool (200 µL or 
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2000 µL). Subjects exposed to distilled water—and thus essentially air—were labelled with the 
term “VAir”, while those exposed to linalool were given the prefix “L200-” or “L2000” 
depending on whether they were exposed to 200 μL or 2000 μL (per spice jar) respectively.  
Immediately following this odor treatment session, intracranial drug deliveries were 
conducted. Intra-NAcSh microinfusions were conducted using microinjectors attached to a 
Hamilton syringe, performed over a 1-minute time period. Microinjectors were kept in place for 
an additional 1-minute time period following infusion to allow for maximum diffusion from the 
injector tips. Subjects treated with PBS solutions were designated with the term “VPBS”, while 
those given bilateral administration of 5 ng/0.5μL CBD were labelled with the term “-CBD.” 
Following this, animal subjects were then immediately exposed to designated test procedures. 
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2.4 Chronic Unpredictable Stress Protocol 
The Chronic Unpredictable Stress (CUS) Protocol was a protocol designed by previous 
lab member Dr. Justine Renard to simulate the acquirement of chronic stress in designated rat 
subjects. The protocol involved 14 consecutive days of unpredictable stress activities, including 
supra-threshold footshocks (0.6 mA), food and water deprivation, wet bedding, the tilting of rat 
plexiglass home cages at a 45° angle, and sudden light deprivation. Following the 14-day 
protocol, food, water, and housing conditions returned to previous controlled conditions and 
animal behavioral testing began immediately. Subjects exposed to the CUS protocol were 
labelled with the prefix “CUS-” to specify their chronically stressed nature; these subjects were 
then compared with treatment group interventions to determine whether these interventions were 
effective in reversing chronic-stress induced cognitive changes acquired from exposure to the 
CUS protocol. 
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2.5 Experimental Cohorts and Treatment Group Designations 
 Aside from the aforementioned baseline and chronic stress cohorts (the latter employing 
the CUS protocol to induce chronic stress within subjects), separate experimental cohorts 
received intra-NAcSh flumazenil and EPA administration to test whether GABAAR and/or ERK 
activity were potentially correlated with behavioral effects associated with CBD-Linalool 
administration. The final group designation summary is illustrated in the table below. 
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2.5 Behavioral Testing 
2.5.1 Open Field Test.  
This task is a sensorimotor test which measured overall locomotor activity and 
thigmotaxis of rat subjects. The test apparatus consists of a transparent plexiglass box that 
assesses various motor movements using a grid system of laser interference detection (San Diego 
Instruments). Center and total distance travelled (in cm) by rat test subjects were recorded during 
30-minute test sessions for data analyses, with the first 5 minutes of behavioral observations 
being assessed for locomotor and thigmotaxic measures.  
2.5.2 Light Dark Box Test. 
 This task measured the bright-space anxiety exhibited by rats, based upon the rats’ 
instinctive tendency to avoid bright-lit environments. The test apparatus comprised of a two-
compartment non-transparent plexiglass box (50 x 25 x 37 cm), with a white-coloured, 
uncovered compartment and a black-coloured, lidded compartment. A 10 by 10 cm open 
doorway separated these different compartments, allowing rat subjects to easily traverse between 
the two compartments. The white-coloured compartment was brightly lit by an overhead lamp 
located approximately 125 cm above the floor of this respective compartment. To begin the 
experimental session, the rat was placed in the white-coloured compartment with its back facing 
the open doorway. Rats were then observed for a total of 5 minutes, with measurements such as 
total time spent in the light, risk assessment, latency to first compartmental and second 
compartmental transitions, as well as total number of transitions during the test session. 
Transitions between compartments were deemed complete when all four feet of the rat were 
placed in the new compartment. Risk assessment measures included times when the rat was in 
the dark compartment and placed at a minimum its nose into the light compartment, with the 
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maximum inclusion criteria being three of four paws in the light compartment. Test sessions 
were recorded and analyzed offline (Behaview software; www.pmbogusz.net). 
 
2.5.3 Social Motivation and Recognition  
 
The Social Motivation and Recognition test, otherwise known as the Three-Chamber 
Sociability and Social Memory test, is a three-stage test used to assess the degree of sociability 
and social recognition memory, as described by Loureiro et al. (2015). The first stage of 
habituation was a 13-minute session whereby the subject could explore the test apparatus and 
become familiar with the environment. The next day, within a span of 24 hours, the subject was 
placed again within the center chamber for a 5-minute session with the chamber gates down. 
After this 5-minute session, the second stage of social motivation and third stage of social 
recognition were conducted in successive order. The second stage involved placing an empty 
small wired cage and another one filled with a stranger male rat within the left and right 
chambers; chamber gates were then lifted, and the test subject’s time spent interacting with each 
cage was recorded for 8 minutes. Immediately after the second stage, a novel male rat was 
introduced into the empty wired cage, rendering the cage already with a rat from the first stage 
the “familiar rat”; the subject’s total interaction time with each cage was then recorded for 
another 8-minute session. Throughout the testing protocol, the empty wired cage and stranger rat 
wired cage in the second stage of the test were counterbalanced between the left and right 
chambers of the test apparatus. Subjects’ recorded interaction times with the cages during the 
task was analyzed offline (Behaview software; www.pmbogusz.net).  
2.5.4 Elevated Plus Maze 
 
This task involved a black acrylic maze apparatus with four arms (10 x 50 cm), extending 
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from a 10 x 10 cm base platform elevated 50 cm above the floor. Two opposite arms were 
shielded with 40 cm-high walls, while the remaining two opposing arms were unshielded except 
for a 1 cm-high ledge that served to prevent subjects from falling off the platform while 
exploring. The elevated plus maze task measures open-space anxiety, with primary outcomes 
including total time spent in open arms, risk assessment (total time spent by the subject placing 
at a minimum its nose, or at a maximum three of its paws in the open arm area) and total number 
of arm transitions. Rat subjects were placed on the center platform facing an open arm and 
allowed to explore the maze apparatus for 10 minutes. Exploration behavior was recorded and 
analyzed offline (Behaview software; www.pmbogusz.net). 
2.5.5 Context-Dependent Fear Conditioning 
 
As an associative learning and memory task, context-dependent fear conditioning 
measures the degree of freezing behavior exhibited by rats following the formation or recall of a 
previously acquired associative fear-memory between a footshock stimulus and a specific 
sensory or contextual cue. Using the same test apparatus described previously (Norris et al. 
2016), the task involved two stages: conditioning and testing. Conditioning (Stage 1) involved 
pairing contextual stimuli (in the form of a black-and-white striped walled, lidless box) to supra-
threshold footshocks (0.8 mA, 1 second in duration, 10 total administered at randomized 
intervals over a 25 minute session) delivered via a metallic grid shock floor located at the base of 
the box enclosure. The next day, within 24 hours, rat subjects were re-introduced to the same test 
environment (Stage 2) and their subsequent freezing behavior recorded. Treatment effects for the 
acquisition phase of fear memory was assessed by administering treatment immediately prior to 
the conditioning phase; in contrast, to examine the effects of drug interventions to modulate the 
recall of fear memory formation was tested by administering treatment immediately prior to the 
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testing (recall) phase of the procedure. Recorded data was then analyzed in an offline manner 
(Behaview software; www.pmbogusz.net).   
2.5.6. Spontaneous Alternation 
 
This test assesses the rats’ spatial working memory and examines the ability of the rat to 
hold short term memory (i.e. having just visited a specific maze arm) during the performance of 
the task. Normally, healthy rats will alternate between the test arms but will continue to re-enter 
the just experienced arms when there is a working memory deficit. A Y-maze (black acrylic, 3 
arms separated by angles of 120˚ from one another; each arm length was 50 cm with a wall 
height of 40 cm) was placed on the floor and rats were placed at the end of a designated starting 
arm facing the wall. Subjects were then allowed to explore the maze apparatus and alternate 
between arms during a 15-minute session. A successful arm entry was classified as all four paws 
of the rat had either entered or left an arm, and a successful set of alternations was defined by 
three consecutive entries into unique arms (e.g. entry into arm A, then B, then C). Subjects’ 
exploratory behaviors were recorded and analyzed offline (Behaview software; 
www.pmbogusz.net). 
2.5.7 Novel Object Recognition 
 
The novel object recognition test examines a rat’s ability to discern between novel and 
familiar objects, representative of short or long-term memory (depending on the retention 
interval). Healthy rats will recall an object previously encountered, preferring the choice of a 
novel object when given a choice to explore a recently encountered vs. novel object in the test 
chamber. This ability is impaired during memory impairments, whereby rats will show deficits in 
discerning between the previously encountered vs. novel object during the object exploration 
test. The test apparatus comprised of an 80 x 80 cm lidless box (black acrylic). Subjects were 
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exposed to the box for a 20-minute session one day prior to the actual test to allow them to 
habituate to this novel environment. Testing day consisted of two stages, each 3 minutes in 
length. During the first stage, subjects were placed in the test box that contained two identical 
objects in two corners (15 cm away from each box wall, with both corners being shared by a 
single side). Following the 3-minute session, subjects were returned to their housing cages. One 
hour later, subjects were re-introduced to the box with one of the former objects replaced at the 
same previous corner location. Designations for novel-familiar object alternations were 
counterbalanced between subjects. The time subjects spent sniffing the object (deemed as 
exploratory behavior) was recorded and analyzed offline (Behaview software; 
www.pmbogusz.net).  
2.5.8 Testing Timelines 
 Shown below are the different test cohorts and their associated behavioral assays, 
organized in a chronological manner and beginning from day 1 of testing or protocol exposure:  
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2.6 Molecular Analyses 
At the end of experimental tests prior to euthanasia, rats were given one last drug and 
odour administration (as previously described) based upon their respective treatment group 
designations during behavioral testing. Subjects were then injected intra-peritoneally with an 
overdose of sodium pentobarbital (240 mg/kg, i.p., EuthanylTM) and decapitated. Brains were 
extracted and then flash frozen at –80°C. Coronal sections (99 µm) of the brains containing the 
PFC, and NAcSh were sliced using a cryostat and mounted on glass slides; bilateral 
microdissections were then taken from the specified brain regions (NAcSh microdissections 
were taken from around the infusion site to avoid any regions with active gliosis). Tissue 
samples were homogenized using a Dounce homogenizer and proteins were then isolated using 
lysis buffer containing phosphatase and protease inhibitors. Protein quantification was conducted 
using the bicinchoninic acid (BCA) assay.  
The western blotting procedure was conducted in the same manner as previously 
described by Lyons et al. (2013), with protein samples being denatured in Laemmli buffer and 
diluted to ensure all concentrations were equal and each well loaded with 25 µg of protein. 
Samples underwent SDS polyacrylamide gel electrophoresis (SDS-PAGE) at 125V for 1.5 hours 
in 10% acrylamide gels, followed by transference to nitrocellulose membranes using the Trans-
Blot Turbo Transfer System (Bio-Rad) at 2.5A for 10 minutes. After blocking with 2.5% bovine 
serum albumin (BSA) in TBS-T for one hour, membranes were then placed in blocking solution 
containing the following primary antibodies with their respective host species and dilutions as 
follows: α-tubulin (mouse; 1:10,000; Sigma-Aldrich), phosphorylated GSK3α/β ser21/9 (p-
GSK3α/β; rabbit; 1:1000; Cell Signaling Technology), total GSK3α/β (t-GSK3α/β; mouse; 
1:250; Santa Cruz Biotechnology), phosphorylated AktSer473 (p-AktSer473; rabbit; 1:1000; 
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Cell Signaling Technology), phosphorylated AktThr308 (p-AktThr308; rabbit; 1:750; Cell 
Signaling Technology), total Akt (t-Akt; mouse; 1:1000; Cell Signaling Technology), 
phosphorylated ERK1/2 (p-ERK; rabbit; 1:1000; Cell Signalling Technology), total ERK1/2 (t-
ERK; mouse; 1:2000; Cell Signalling Technology), phosphorylated JNK (p-JNK; rabbit; 1:1000; 
Cell Signalling Technology), total JNK (t-JNK; rabbit; 1:1000; Cell Signalling Technology).  
Membranes were finally probed with species appropriate fluorophore-conjugated 
secondary antibodies (LI-COR IRDye 680RD and IRDye 800CW; Thermo Scientific) at a 
dilution of 1:10000. LI-COR Odyssey Infrared Imaging System and Image Studio analysis 
software were then used to scan and obtain densitometry measurements respectively, 
normalizing the intensity of each sample’s target protein band to its respective α-tubulin band 
intensity. 
2.7 Histology 
Rat subjects were euthanized, with their brains extracted and sliced as previously 
mentioned in section 2.6. Following tissue extraction procedures as described in section 2.6 
regarding western blotting, slides with PFC and NAcSh coronal sections were then stained with 
cresyl violet dye as detailed by Loureiro et al. (2015). Sections with visible cannula tip sites 
viewed under a microscope were photographed and correlated with their respective locations as 
according to the rat brain atlas by Paxinos and Watson (2005) for placement accuracy. 
2.8 Statistical Analyses 
All statistical analyses were performed using SPSS (IBM SPSS Statistical Package 
Version 26). Preliminary analyses for normal distribution were conducted for both behavioral 
and molecular data (normalized densitometry measurements) using the Kolmogorov-Smirnov 
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test, followed by either Two-way t-tests or One-way ANOVA analyses where appropriate; post-
hoc analyses were conducted utilizing Fischer’s LSD test. All statistical significances were 
denoted by p < 0.05, with a 95% confidence interval. 
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3. Results: Behavioral Assays 
3.1 Baseline Cohort Behavioral Results 
3.1.1 Open Field Test 
 
 The open field test was conducted primarily to assess potential alterations in locomotor 
activity, and secondarily as an open-space anxiety measure (Figure 6). One-way ANOVA tests 
demonstrated that there were no significant differences in total distance travelled between 
treatment groups in the baseline cohort (F(5, 57) = 1.332, p = 0.264; figure 6B) ultimately 
suggesting no significant differences in locomotor ability between treatment groups in their 
respective test analyses.  
 In summary, these baseline cohort results from the open field test demonstrated that no 
significant locomotor abnormalities resulted from treatment interventions in the cohort—
effectively eliminating the potential of locomotor abnormalities confounding the results of all 
subsequent behavioral assays which inherently involve locomotion to some degree.  
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3.1.2 Light Dark Box Test 
 The light dark box test was used to assess bright-space anxiety exhibited by treatment 
groups. As shown in figure 7, when measuring total time spent in the light compartment, both 
L200-CBD and L2000-CBD presented significantly increased time spent exploring the light 
chamber compared to all other treatment groups (p ≤ 0.01 for all group comparisons except when 
comparing L200-CBD with L2000-CBD) in the baseline cohort (F(5, 56) = 6.752, p ≤ 0.001; figure 
7B).  
 The secondary assessment of bright-space anxiety, the total number of transitions made 
by test subjects, also differed significantly between treatment groups in the baseline cohort (F(5, 
56) = 5.775, p ≤ 0.001; figure 7C). Interestingly, while the L2000-CBD treatment group exhibited 
significantly higher number of transitions between compartments compared to all other groups (p 
≤ 0.05) except L200-CBD (p = 0.074), the L200-CBD treatment group only exhibited 
significantly higher number of transitions when compared to the VAirVPBS and VAirVCBD groups 
(p ≤ 0.05). In addition, the L2000-VCBD group presented significantly higher total number of 
compartmental transitions compared to the VAirVPBS group (p = 0.016).  
 These LDB test results strongly suggest the presence of an Entourage Effect (EE) 
between CBD and linalool which was supra-additive in its anxiolytic effects relative to sub-
threshold doses of either alone, given that the L2000-CBD group exhibited significantly reduced 
bright-space anxiety compared to the VAirVPBS group, as well as its component vehicle groups 
VAirCBD and L2000-VPBS in both anxiety assessment measures (total time in light, total number 
of transitions). Results also suggest that this EE-potentiated bright-space anxiolysis is present in 
a lesser degree following L200-CBD treatment, as the L200-CBD group exhibited significantly 
reduced bright-space anxiety compared to the VAirVPBS group, VAirCBD and L200-VPBS groups 
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in the primary anxiety measure (total time in light) but not the secondary anxiety measure (total 
number of transitions). 
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3.1.4 Social Motivation and Recognition Test 
 To assess sociability and social recognition memory as a pre-clinical model of social 
anxiety disorder, the social motivation and recognition test was employed with results as shown 
in figure 8. Sociability and social recognition memory were respectively quantified as social 
motivation index (SMI) and social recognition index (SRI) values. SMI values were expressed as 
the normalized absolute difference of time spent sniffing the two cages in stage 2 (social 
motivation), while SRI values were expressed as the normalized absolute difference of time 
spent sniffing the two cages in stage 3 (social recognition). 
Ultimately, significant differences in stage 2 social motivation index and stage 3 social 
recognition index values were not found between groups in the overall ANOVA analysis of the 
baseline cohort (stages 2 and 3 respectively: F(5, 44) = 1.127, p = 0.360 [figure 8B]; F(5, 44) = 
0.714, p = 0.616 [figure 8C])  
 Taken together, these SMI and SRI findings of non-significance in the baseline cohort 
suggest respectively that there are no significant differences in social novelty preference and 
social recognition memory between treatment groups—and consequently that the combination 
treatments of linalool and cannabidiol do not elicit an EE-potentiated change in social cognition, 
at least in the baseline cohort. This result is not particularly surprising however as previous 
studies in our lab have demonstrated that social anxiety induced cognitive alterations generally 
only occur following chronic stress exposure or other neurodevelopmental toxic insults (e.g. 
Renard et al., 2017). 
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3.1.3 Elevated Plus Maze Test 
 The open space anxiety of test subjects was assessed using the Elevated Plus Maze 
behavioral assay. Regarding the time spent in open arms which represents the primary measure 
of open space anxiety in this test, as shown in figure 9, one-way ANOVA analysis revealed no 
significant differences between groups in the baseline cohort (F(5, 53) = 1.690, p = 0.153; figure 
9B).  
 Within the secondary open space anxiety measure of total arm transitions, no significant 
differences in transition counts between open and closed arms were discovered between groups 
in the baseline cohort (F(5, 53) = 0.386, p = 0.856; figure 9C). 
Taking into account the findings of non-significance in both the EPM assessments of 
total in open arms and total arm transitions in the baseline cohort, this suggests that there were no 
differences between groups in the perception of open-space anxiety in the more sensitive EPM 
apparatus (as compared to the OFT apparatus); consequently, these findings present the lack of 
EE-potentiated open-space anxiety within the context of the EPM test paradigm following 
combination treatments of linalool and cannabidiol. 
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3.1.5 Context-Dependent Fear Conditioning 
 The context-dependent fear conditioning (CFC) behavioral assay assessed context-
dependent anxiety observed through freezing time presentation. As demonstrated in figure 10, in 
the context of the CFC-Acquisition (as previously described), significant differences in freezing 
time were found in the baseline cohort (F(5, 47) = 3.195, p = 0.015; figure 10B). The L200-CBD 
group exhibited significantly lower freezing time when compared to solely the VAirVPBS and 
L200-VPBS groups (p ≤ 0.05); the L2000-CBD group however demonstrated significantly lower 
freezing time compared to all treatment groups (p ≤ 0.05) except its lower dose L200-CBD 
counterpart (p = 0.668). 
 Significant differences were also found between groups in the baseline cohort when 
assessing CFC-Recall (F(3, 34) = 6.360, p = 0.002; figure 10C). The L2000-CBD group was found 
to exhibit significantly lower freezing time compared to all other groups (p ≤ 0.05).  
 In summary, these CFC assay results demonstrate that the L2000-CBD treatment was 
able to significantly reduce the context-dependent anxiety induced by the CFC apparatus in both 
the CFC-Acquisition and CFC-Recall challenges. This in turn suggests that the EE-potentiated 
anxiolysis induced by L2000-CBD in this behavioral assay is effective in attenuating both fear 
memory formation and recall, as shown respectively by the results from the CFC-Acquisition 
and CFC-Recall challenges, strongly suggesting a strong entourage effect for the combinatorial 
effects of CBD and linalool, relative to either compound alone. 
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3.2 Flumazenil Challenge Behavioral Results 
 In light of the results from the baseline cohort suggesting the presence of an EE-
potentiated anxiolysis following L2000-CBD treatment, the flumazenil challenge—involving 
groups that received intra-cranial flumazenil alongside L2000-CBD treatment—was conducted 
to determine whether this EE-potentiation involved GABAAR activity modulation, given that 
previous studies have shown that linalool and CBD may generate anxiolysis via GABAAR 
mechanisms of action (Bakas et al., 2017; Harada et al., 2018; Lopes et al., 2012; Milanos et al., 
2017). 
3.2.1 Open Field Test 
The OFT was used to identify potential alterations in locomotor activity and secondarily 
as an open-space anxiety measure in the flumazenil cohort (Figure 11). One-way ANOVA tests 
demonstrated that there were no significant differences in total distance travelled between 
treatment groups in the flumazenil challenge cohort (F(3, 26) = 0.339, p = 0.798; figure 11A), 
ultimately suggesting no significant differences in locomotor ability between treatment groups. 
 When assessing thigmotaxis anxiety measures of center-to-total locomotion ratios 
(expressed as a percentage), ANOVA analysis revealed significant differences between treatment 
groups (flumazenil: F(3, 32) = 10.06, p ≤ 0.01; figure 11B); post hoc analyses showed that the 
L2000-CBD treatment group exhibited significantly higher center/total locomotion (%) 
compared to all other treatment groups (p ≤ 0.05). 
 These flumazenil challenge OFT results demonstrated that no significant locomotor 
abnormalities resulted from treatment interventions in the cohort, removing concerns of 
locomotor abnormalities confounding interpretations of results from subsequent behavioral 
assays which all involve locomotion. Furthermore, the center/total locomotion (%) results 
51 
 
suggest that intra-cranial flumazenil administration is effective in removing the EE-potentiated 
open-space anxiolysis exhibited by L2000-CBD group, as demonstrated by the significantly 
reduced center/total locomotion (%) value following co-administration of L2000-CBD and 
flumazenil. 
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3.2.2 Light Dark Box Test 
The LDB test was used to assess bright-space anxiety exhibited by treatment groups 
using the same primary and secondary anxiety measures assessed in the baseline cohort (total 
time in light compartment, total compartmental transitions). Within the flumazenil challenge 
cohort, significant differences in total time spent in the light compartment between groups was 
discovered through one-way ANOVA analysis (F(3, 31) = 18.89, p ≤ 0.001; figure 12A), with the 
L2000-CBD group presenting significantly greater time in the light compartment than all other 
treatment groups (p ≤ 0.001). 
Furthermore, one-way ANOVA analysis revealed significant differences in terms of total 
transition counts between treatment groups in the flumazenil challenge cohort (F(3, 31) = 18.191, p 
≤ 0.001; figure 12B). Specifically, post hoc analyses revealed the number of total transitions 
made by the L2000-CBD to be significantly higher than all other treatment groups (p ≤ 0.001). 
These flumazenil challenge LDB test results demonstrated that intra-cranial flumazenil 
administration was able to effectively eliminate the EE-potentiated anxiolysis elicited following 
L2000-CBD treatment, as shown with the significant reduction in both total time in the light 
compartment and total compartmental transitions exhibited by the co-treated L2000-
CBD+flumazenil group.   
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3.2.3 Context-Dependent Fear Conditioning (Recall) 
Utilizing the same CFC test apparatus employed in baseline cohort testing, context-
dependent anxiety (specifically with treatment given immediately prior to stage 2 testing) 
observed through freezing time presentation was assessed in the flumazenil challenge cohort. As 
shown through one-way ANOVA and subsequent post-hoc analyses in figure 13, the L2000-
CBD group also presented significantly lower freezing time compared to all other treatment 
groups (F(3, 32) = 19.283, p ≤ 0.001). 
 Conversely, when taking account the non-significance in freezing time between the 
L2000-CBD+flumazenil group and the two vehicle groups (VAirVPBS, VAir+Flumazenil) as well 
as the significantly higher freezing time presented by the L2000-CBD+flumazenil group when 
compared to the flumazenil-free L2000-CBD group (p ≤ 0.05), these results suggest that intra-
cranial flumazenil administration is able to prevent the presentation of EE-potentiated fear-
memory anxiolysis induced by L2000-CBD treatment in the CFC-Recall challenge condition.  
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3.3 EPA Challenge Behavioral Results 
Given that baseline cohorts indicated the presence of EE-potentiated anxiolysis following 
L2000-CBD treatment, the EPA challenge—involving groups that received intra-cranial EPA 
(ERK activator) alongside L2000-CB treatment—was carried out to determine whether this EE-
potentiation involved ERK activity modulation, as previous studies have suggested that linalool 
and CBD may yield anxiolysis through regulation of pERK activity (Caputo et al., 2016; 2017; 
2018; Hudson et al., 2019). 
3.3.1 Open Field Test 
 Employing the OFT assay used in the flumazenil challenge cohort, total distance 
travelled and thigmotaxis activity of treatment groups were assessed to respectively determine 
the presence of any differences in locomotion and open-space anxiety between treatment groups 
in the EPA challenge cohort. 
 OFT results from the EPA challenge cohort demonstrated no significant differences 
between treatment groups in the assessment of total locomotion (F(3, 34) = 0.993, p = 0.409; 
figure 14A); however, significant differences between groups were found when assessing 
center/total locomotion (%), with the L2000-CBD treatment exhibiting significantly increased 
center/total locomotion (%) values (p ≤ 0.05) in comparison to all other groups (F(3, 34) = 10.688, 
p ≤ 0.01; figure 14B). 
These OFT findings presented by the EPA challenge cohort demonstrate that no 
significant locomotor abnormalities resulted from treatment interventions in the cohort, 
indicating that there were no locomotor abnormalities present that would potentially confound 
interpretations of results from subsequent behavioral assays involving locomotion. In addition, 
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the center/total locomotion (%) results suggest that intra-cranial EPA administration is effective 
in removing the EE-potentiated open-space anxiolysis exhibited by L2000-CBD group, as shown 
by the significantly reduced center/total locomotion (%) value following co-administration of 
L2000-CBD and flumazenil in conjunction with the non-significance between the L2000-
CBD+flumazenil and the two vehicle groups (VAirVPBS, VAir+EPA). 
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3.3.2 Light Dark Box Test 
Utilizing the LDB test in the same manner as in the baseline and flumazenil challenge 
cohorts, bright-space anxiety exhibited by EPA challenge treatment groups was assessed through 
the primary measure of total time in the light compartment and secondarily through the measure 
of total compartmental transitions.  
Within the EPA challenge cohort, one-way ANOVA analysis revealed significant 
differences in total time spent in the light compartment between treatment groups (F(3, 35) = 
7.644, p = 0.001; figure 15A), with post hoc analyses demonstrating that the L2000-CBD group 
presented significantly greater time spent in the light compartment compared to all other groups 
(p ≤ 0.05). A similar trend was observed in regard to total compartmental transitions, with one-
way ANOVA analysis demonstrating significant differences between treatment groups (F(3, 35) = 
11.921, p ≤ 0.01; figure 15B) and post hoc analyses showing that the L2000-CBD group 
exhibited a significantly increased amount of compartmental transitions compared to all other 
groups (p ≤ 0.05). 
 The significantly decreased total time spent in the light compartment and compartmental 
transitions exhibited by the L2000-CBD+EPA treatment group when compared to the EPA-free 
L2000-CBD group, concurrent with non-significance when compared to the VAirVPBS and 
VAir+EPA vehicle groups suggests that intra-cranial EPA administration is capable of preventing 
the EE-potentiated bright-space anxiolysis induced by L2000-CBD treatment. 
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3.3.3 Context-Dependent Fear Conditioning (Acquisition) 
Employing the same CFC test apparatus used in previous cohort testing, context-
dependent anxiety—specifically with treatment given prior to the stage 1 conditioning phase—
was observed through freezing time presentation was assessed in the EPA challenge cohort.  
As demonstrated in figure 16, one-way ANOVA analysis revealed significant differences 
between treatment groups in the assessment of freezing time (F(3, 34) = 5.548, p = 0.004; figure 
16); post hoc analyses further showed that the L2000-CBD treatment group exhibited 
significantly greater time spent frozen when compared to all other groups (p ≤ 0.05). 
Notably, given that the L2000-CBD+EPA treatment group exhibited non-significant 
differences in freezing time when compared to vehicle groups (VAirVPBS, VAir+EPA) and that it 
presented significantly increased freezing time in comparison to its EPA-free L2000-CBD 
treatment counterpart, these results suggest that intra-cranial EPA administration is effective in 
preventing the presentation of EE-potentiated fear-memory anxiolysis elicited by L2000-CBD 
treatment in the CFC-Acquisition challenge condition. 
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3.4 Chronic Stress Behavioral Results 
The previous studies explored the ability of CBD + linalool combinations to produce 
acute anxiolytic effects in otherwise healthy rat cohorts. However, given that most chronic 
anxiety disorders are experienced following prolonged exposure to environmental stressors, we 
next explored the potential effects of CBD + linalool combinations in mitigating anxiogenic 
effects induced by chronic stress exposure (see methods). Following the findings from the 
baseline cohort suggesting that L2000-CBD treatment is capable of eliciting an EE-potentiated 
anxiolysis in various contexts, chronic stress models were generated using the CUS protocol 
employed in this study and incorporated into a chronic stress cohort to determine whether 
L2000-CBD treatment was capable of reversing alterations induced by chronic stress—and 
secondarily if such a reversal was potent enough to induce the originally observed Entourage 
Effect seen in the baseline cohort. 
3.4.1 Open Field Test 
 Utilizing the OFT assay employed in previous cohorts, the locomotion and center/total 
locomotion (%) of chronic stress cohort treatment groups were assessed to respectively 
determine if any significant differences in locomotor or open-space anxiety were present 
between groups. 
 One-way ANOVA analysis of total locomotion (F(3, 29) = 0.833, p = 0.487; figure 17A) 
and center/total locomotion (%) (F(3, 32) = 1.115, p = 0.359; figure 17B) revealed no significant 
differences between treatment groups in the chronic stress cohort. In addition, a pre-planned two-
tailed t-test comparison between the VAirVPBS and CUS-VAirVPBS treatment groups revealed no 
significant differences in center/total locomotion (%) (t(14) = 1.022, p = 0.325; figure 17B—not 
visualized due to insignificance). 
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 Collectively, these results indicate that there were no significant locomotor differences 
between groups that could confound the interpretation of results from subsequent behavioral 
assays involving an element of locomotion. Furthermore, these findings suggest that the chronic 
stress resulting from exposure to the 2-week CUS protocol employed in this study is not 
effective in achieving significant stress-induced open-space anxiety in the OFT paradigm (as 
shown by the non-significance between the VAirVPBS and CUS-VAirVPBS treatment groups). 
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3.4.2 Spontaneous Alternation  
The spontaneous alternation (SA) behavioral paradigm was used to assess potential 
working memory deficiencies between treatment groups in the chronic stress condition, with 
results as shown in figure 18B. When assessing normalized alternation counts (expressed as a 
percentage value in relation to total entry counts), no significant differences were found between 
groups (F(3, 29) = 1.986, p = 0.138; figure 18B). A pre-planned two-tailed t-test comparison 
between the VAirVPBS and CUS-VAirVPBS treatment groups presented no significant differences 
(t(14) = 1.627, p = 0.126; figure 18B—comparison not visualized due to non-significance). 
The insignificance in normalized alternation counts (%) found between groups in the SA 
test ultimately suggests that there is lack of comparable memory deficits between said treatment 
groups. Furthermore, pre-planned comparison results between VAirVPBS and CUS-VAirVPBS 
treatment groups suggests that the 2-week CUS protocol used in this study was not sufficient in 
generating a chronic stress-induced model of cognitive impairment. Nevertheless, an important 
implication from these results is that the combination of CBD + linalool (at doses which are 
highly anxiolytic), did not produce any cognitive impairments in and of themselves, relative to 
VEH controls, suggesting that the potential therapeutic properties of CBD + linalool are free of 
negative cognitive side effects, which, as previously discussed, are serious clinical limitations to 
most commonly used anxiolytic medications. 
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3.4.3 Novel Object Recognition 
Long-term memory capacity was assessed through observations of object discrimination 
by test subjects from the chronic stress cohort in the novel object recognition assay.  
Significant differences in the novelty preference score, which measured novelty 
preference in relation to overall exploration time of assigned objects, were not found between 
treatment groups in the chronic stress cohort following one-way ANOVA analysis (F(3, 26) = 
0.693, p = 0.565; figure 19B). Furthermore, pre-planned two-tailed test comparisons between the 
VAirVPBS and CUS-VAirVPBS treatment groups presented no significant differences (t(13) = 0.489, p 
= 0.647; figure 19B—comparison not visualized due to non-significance). 
This lack of significant differences observed in the NOR paradigm suggests that there 
were no relative deficiencies in long-term memory cognition between treatment groups in the 
chronic stress cohort. In addition, lack of significant differences between the VAirVPBS and CUS-
VAirVPBS treatment groups following pre-planned comparison analysis suggests that the 2-week 
CUS protocol used in this study was not sufficient in generating a chronic stress-induced model 
of cognitive impairment. Again, similar to results observed with spontaneous alternation, these 
findings suggest that the potential therapeutic properties of CBD + linalool for anxiolysis are free 
of negative cognitive side effects. 
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3.4.4 Light Dark Box Test 
The LDB assay was used to assess for differences in bright-space anxiety between 
treatment groups within the chronic stress cohort, utilizing the same primary measure of total 
time spent in the light compartment and secondary measure of total compartmental transitions 
employed in previous cohorts. 
One-way ANOVA and subsequent post hoc analysis of chronic stress cohort data 
revealed significant differences between treatment groups, with both the CUS-L2000-CBD and 
non-stressed L2000-CBD treatment groups exhibiting significantly increased exploration time in 
the light compartment (p ≤ 0.05) compared to VAirVPBS and CUS-VAirVPBS (F(3, 27) = 5.824, p ≤ 
0.003; figure 20A). In addition, a pre-planned comparison (significance denoted in green) 
between the VAirVPBS and CUS-VAirVPBS treatment groups used to assess the validity of the 
chronic stress model in the context of bright-space anxiety demonstrated significant differences 
between the two groups, with the VAirVPBS group found to spend significantly greater time in 
light than its CUS-VAirVPBS counterpart (t(13) = 2.431, p = 0.030).  
In regard to the secondary measure of bright-space anxiety, the number of total 
transitions made by treatment groups differed significantly (F(3, 27) = 4.218, p ≤ 0.014; figure 
20B), with the CUS-L2000-CBD group presenting significantly greater number of total 
transitions than the CUS-exposed and non-stressed VAirVPBS groups (p ≤ 0.05), while the non-
stressed L2000-CBD group presented only significantly higher total transition counts when 
compared to the CUS-VAirVPBS treatment group (p ≤ 0.05). 
 Taken together, the significant reduction in anxiety symptoms presented by the CUS-
L2000-CBD group when compared to the CUS-VAirVPBS group suggests that L2000-CBD 
administration is effective in attenuating bright-space anxiety induced by chronic stress. 
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Furthermore, the non-significance between L2000-CBD and CUS-L2000-CBD groups and 
significant difference between VAirVPBS and CUS-L2000-CBD groups suggests that the EE-
potentiated bright-space anxiolysis observed in the baseline cohort is also achieved under chronic 
stress conditions. 
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3.4.5 Social Motivation and Recognition Test 
Utilizing the same SMRT assay employed in the baseline cohort, the sociability and 
social recognition memory of treatment groups in the chronic stress cohort were respectively 
assessed through the previously used measures of SMI and SRI.  
While one-way ANOVA analysis revealed no significant differences between treatment 
groups in stage 2 SMI values (F(3, 26) = 1.631, p = 0.206; figure 21A), a pre-planned two-tailed t-
test comparison conducted within the chronic stress cohort between the VAirVPBS and CUS-
VAirVPBS groups revealed the CUS-treated model to elicit significantly lower stage 2 SMI values 
(t(12) = 2.441, p = 0.031; figure 21A—significance comparison shown in green). 
In regard to stage 3 of the SMRT assay, treatment groups in the chronic stress cohort 
demonstrated significantly different SRI values (F(3, 26) = 5.615, p = 0.004; figure 21B). Post hoc 
analyses revealed that the SRI value exhibited by the stressed VAirVPBS group was significantly 
lower when compared to all other treatment groups (p ≤ 0.05). 
In summary, these SMRT assay results from the chronic stress cohort suggest that the 
CUS protocol employed in this study was effective in generating chronic stress-induced social 
cognition impairments, as exemplified by the pre-planned comparison in figure 21A and the one-
way ANOVA analysis in figure 21B. Furthermore, stage 3 SRI value analysis suggests that 
L2000-CBD treatment was effective in reversing the social recognition memory deficits induced 
by chronic stress exposure, as demonstrated by the significantly higher SRI values of the CUS-
L2000-CBD group compared to the CUS-VAirVPBS group. 
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3.4.6 Elevated Plus Maze 
The EPM assay was utilized in the chronic stress cohort in the same manner as done 
previously with the baseline cohort, assessing open-space anxiety through the primary measure 
of time spent in open arms and the secondary measure of total arm transitions.  
One-way ANOVA analysis revealed significant differences in open arm exploration time 
between treatment groups in the chronic stress cohort (F(3, 28) = 3.391, p = 0.032; figure 22A), 
with subsequent post hoc analysis showing that the L2000-CBD and CUS-L2000-CBD groups 
exhibited significantly greater open arm exploration time in comparison to the CUS-VAirVPBS 
group (p ≤ 0.05). A pre-planned comparison conducted between VAirVPBS and CUS-VAirVPBS 
groups assessing open arm exploration time (in an attempt to investigate the ability of the CUS 
protocol to generate chronic-stress induced open-space anxiety) yielded no significant 
differences (t(14) = 1.872, p ≤ 0.082; figure 22A—significance comparison not visualized due to 
non-significance). Nevertheless, there were strong trends towards the CUS inducing significant 
anxiogenic effects relative to non-stressed controls. 
With regards to the secondary measure of open-space anxiety in the EPM assay, one-way 
ANOVA analysis demonstrated significant differences in arm transition counts between 
treatment groups in the chronic stress cohort (F(3, 28) = 3.433, p = 0.030; figure 22B). Post hoc 
analyses specifically revealed a significant increase in arm transitions committed by both the 
L2000-CBD and CUS-L2000-CBD groups when compared to the CUS-VAirVPBS group (p ≤ 
0.05).  
 These EPM assay results from assessment of the chronic stress cohort ultimately suggest 
that while the CUS protocol was ineffective in inducing significantly increased open-space 
anxiety in the EPM behavioral paradigm, L2000-CBD treatment was nonetheless effective in 
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reversing moderate open-space anxiety induced by chronic stress. 
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4. Results: Molecular Assays (Baseline Cohort) 
Within the context of the baseline cohort, the molecular biomarkers previously described 
in the introduction (GSK-3β, Akt, ERK and JNK) were quantified to in an attempt to elucidate 
potential mechanisms of action correlating with various degrees of anxiolytic efficiency 
displayed in behavioral assays. Two sets of ANOVA analyses were conducted for each protein 
quantified, with one focused on comparing linalool vehicle groups to the double-control group 
(VAirVPBS) within the NAcSh region (referred to as the “control analysis”), while the other 
focused on comparing both L200-CBD and L2000-CBD to VAirVPBS and VAirCBD in both the 
NAcSh and PFC regions (referred to as the “experimental analysis”). Both analyses expressed 
levels of protein in comparison to the control group (VAirVPBS) as percentage values. 
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4.1 GSK-3β Protein Analysis 
 As demonstrated in figure 23, one-way ANOVA analysis revealed no significant 
differences in the control analysis (p-GSK-3β: F(2, 10) = 2.173, p = 0.1646 [figure 23A]; T-GSK-
3β: F(2, 10) = 0.9494, p = 0.4193 [figure 23B]; p/T-GSK-3β: F(2, 11) = 0.274, p = 0.7654 [figure 
23C]). Within the experimental analysis, significant differences were found in the NAcSh region 
when assessing p/T-GSK-3β values (F(3, 20) = 4.526, p = 0.0141; figure 23F); analysis of 
differences between groups in p-GSK-3β (F(3, 20) = 1.956, p = 0.1531; figure 23D) and T-GSK-
3β (F(3, 20) = 1.339, p = 0.29; figure 23E) demonstrated non-significance. Post hoc analysis of 
p/T-GSK-3β values revealed that the VAirCBD group exhibited significantly increased levels in 
comparison to both VAirVPBS and L2000-CBD groups (p ≤ 0.05). Significantly different levels of 
GSK-3β were also exhibited by treatment groups in PFC samples when analyzing p/T-GSK-3β 
(F(3, 27) = 3.642, p = 0.0251; figure 23I) and p-GSK-3β (F(3, 27) = 3.554, p = 0.0274; figure 23G) 
values; no significance was found when assessing levels of T-GSK-3β (F(3, 27) = 0.3919, p = 
0.7598; figure 23H). In both the post hoc assessments of p/T-GSK-3β and p-GSK-3β values, the 
VAirCBD group exhibited significantly increased levels in comparison to both VAirVPBS and 
L2000-CBD groups (p ≤ 0.05). 
 Collectively, given the non-significance observed between the L2000-CBD and VAirVPBS 
treatment in all GSK3β molecular assays conducted in as shown in the experimental analyses, 
these findings suggest that L2000-CBD achieves its EE-potentiated anxiolysis (observed in the 
behavioral tests) without significant modulation of GSK3β activity from baseline levels. 
Furthermore, the lack of effect present following linalool treatment in the control analysis 
suggests that linalool likely does not modulate GSK3β activity on its own; importantly however, 
in light of the significant reduction of p/T-GSK3β levels following L2000-CBD treatment 
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(compared to VAirCBD) in both experimental analyses within the PFC and NAcSh regions, these 
findings suggest that linalool is potentially involved in allosteric modulation of GSK3β activity 
above a certain threshold level—and that this allosteric intervention may serve as a component 
mechanism of action for previously observed EE-potentiated anxiolysis. 
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4.2 Akt Protein Analysis 
 As shown in figure 14, no significant differences were found in the control analysis when 
focusing on either the Ser473 or Thr308 sites following a one-way ANOVA test assessment (p-
AktSer473: F(2, 12) = 1.614, p = 0.2395 [figure 24A]; T-Akt: F(2, 12) = 3.802, p = 0.0526 [figure 
24B]; p/T-AktSer473: F(2, 12) = 1.399, p = 0.2843 [figure 24C]; p-AktThr308: F(2, 12) = 0.8696, p 
= 0.4439 [figure 24A]; T-Akt: F(2, 12) = 3.664, p = 0.0573 [figure 24B]; p/T-AktThr308: F(2, 12) = 
1.862, p = 0.1975 [figure 24C]).  
While no significant differences were found in the NAcSh region when assessing 
AktThr308 sites (p-AktThr308: F(3, 20) = 1.56, p = 0.2302 [figure 24E]; T-Akt: F(3, 20) = 2.527, p 
= 0.0865 [figure 24F]; p/T-AktThr308: F(3, 20) = 1.287, p = 0.3060 [figure 24G]), p-AktSer473 
(F(3, 21) = 0.5449, p = 0.6570; figure 24E) or T-Akt in the context of AktSer473 quantification 
(F(3, 21) = 0.5727, p = 0.6392; figure 24F), significantly different levels of p/T-AktSer473 were 
present in the brain region (F(3, 22) = 5.19, p = 0.0073; figure 24G). Specifically, both the 
VAirCBD group and L200-CBD groups exhibited significantly increased p/T-AktSer473 values 
in comparison to the VAirVPBS and L2000-CBD treatment groups (p ≤ 0.05). 
Similar trends were found in the PFC region (figure 14I/J/K); while no significant 
differences were present following ANOVA analysis of AktThr308 site quantifications (p-
AktThr308: F(3, 21) = 0.5868, p = 0.6304 [figure 24I]; T-Akt: F(3, 30) = 1.148, p = 0.3456 [figure 
24J]; p/T-AktThr308: F(3, 21) = 0.3236, p = 0.8082 [figure 24K]) or the T-Akt assessment of the 
AktSer473 cohort (F(3, 30) = 2.642, p = 0.0674; figure 24J), expression levels of p-AktSer473 and 
p/T-AktSer473 were significantly different between groups (respectively: F(3, 30) = 12.2, p ≤ 
0.001 [figure 24I]; F(3, 30) = 4.536, p = 0.0098 [figure 24K]). With regards to the assessment 
intra-PFC p-AktSer473 levels, the VAirCBD group demonstrated significantly higher levels than 
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all other treatment groups (p ≤ 0.05); when assessing p/T-AktSer473 group comparisons, the 
VAirCBD group exhibited significantly increased expression levels compared to VAirVPBS and 
L2000-CBD treatment groups (p ≤ 0.05), while the L200-CBD group presented significantly 
higher p/T-AktSer473 levels when compared to the VAirVPBS group (p ≤ 0.05).  
Altogether, these Akt molecular assay findings suggest that the EE-potentiated anxiolysis 
elicited following L2000-CBD treatment observed previously in behavioral paradigms likely 
does not involve significant modulation of Akt activity from baseline levels (as evidenced by the 
non-significance in p/T-AktSer473 and p/T-AktThr308 levels between L2000-CBD and VAirVPBS 
treatment groups in both PFC and NAcSh experimental analyses). Furthermore, similar to the 
previous GSK3β analysis, the lack of significant differences between treatment groups following 
linalool administration in the control analysis suggests that linalool likely does not modulate Akt 
activity on its own; however the significant reduction of p/T-Akt levels following L2000-CBD 
treatment (compared to VAirCBD) in both PFC and NAcSh experimental analyses present the 
notion that linalool is potentially involved in allosteric modulation of Akt activity above a certain 
threshold level. Unlike the GSK3β assay however, L200-CBD treatment achieved significantly 
higher p/T-AktSer473 levels in the NAcSh experimental analysis (as well as a moderate increase 
in PFC regional analysis) when compared to the L2000-CBD group, suggesting that a dose-
dependent attenuation of p/T-AktSer473 levels induced through increasing dosages of linalool 
olfactory exposure may be a component mechanism of action through which L2000-CBD 
treatment achieves its EE-potentiated anxiolysis. 
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4.3 ERK Protein Analysis 
 As exhibited in Figure 15, no significant differences were found in the control analysis 
when assessing quantification measures for either the ERK1 isoform (p-ERK1: F(2, 12) = 1.922, p 
= 0.1888 [figure 25A]; T-ERK1: F(2, 12) = 2.709, p = 0.1069 [figure 25B]; p/T-ERK1: F(2, 12) = 
1.117, p = 0.3589 [figure 25C]) or ERK2 isoform (p-ERK2: F(2, 12) = 1.088, p = 0.3681 [figure 
25A]; T- ERK2: F(2, 12) = 2.727, p = 0.1056 [figure 25B]; p/T- ERK2: F(2, 12) = 0.9841, p = 0.4020 
[figure 25C]). 
 Within the context of the NAcSh region, while no significant differences were found in 
T-ERK in either ERK1 (F(3, 19) = 1.884, p = 0.1666; figure 25E) or ERK2 (F(3, 19) = 1.138, p = 
0.3589; figure 25E), there were significantly different intra-NAcSh levels of p-ERK1 (F(3, 19) = 
3.561, p = 0.0337; figure 25D), p/T-ERK1 (F(3, 19) = 4.329, p = 0.0174; figure 25F), p-ERK2 
(F(3, 19) = 4.298, p = 0.0179; figure 25D) and p/T-ERK2 (F(3, 19) = 4.09, p = 0.0213; figure 25F) 
between groups. Post hoc analyses revealed similar trends between phosphorylated levels of 
ERK isoforms versus control and phosphorylated/total levels of ERK isoforms versus control; 
the VAirCBD group presented significantly increased p-ERK1, p-ERK2, p/T-ERK1 and p/T-
ERK2 in comparison to VAirVPBS and L2000-CBD treatment groups (p ≤ 0.05). In addition, 
solely in regard to analysis of p/T-ERK1 and p/T-ERK2 levels, the L200-CBD treatment group 
displayed significantly higher levels of protein ratios when compared to its higher dosage 
counterpart L2000-CBD treatment group (p ≤ 0.05). 
 Similar to the NAcSh region, within the PFC region (Figure 15G/H/I) no significant 
differences were found in regards to T-ERK in both ERK1 (F(3, 22) = 0.2756, p = 0.8424; figure 
25H) and ERK2 (F(3, 22) = 0.564, p = 0.6445; figure 25H); however, significant differences 
between treatment group quantifications of p-ERK1 (F(3, 22) = 8.194, p ≤ 0.001; figure 25G), p/T-
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ERK1 (F(3, 22) = 4.073, p = 0.0192; figure 25I), p-ERK2 (F(3, 22) = 8.656, p ≤ 0.001; figure 25G) 
and p/T-ERK2 (F(3, 22) = 5.549, p = 0.0054; figure 25I) were found. The same pattern of 
significant differences between treatment groups was present in the PFC region, with the 
VAirCBD demonstrating significantly increased p-ERK1, p-ERK2, p/T-ERK1 and p/T-ERK2 
levels in comparison to all other treatment groups (p ≤ 0.05). 
Taken together, these findings from the ERK molecular assay suggest that the EE-
potentiated anxiolysis elicited following L2000-CBD treatment observed previously in 
behavioral paradigms likely does not involve significant modulation of ERK activity from 
baseline levels (as presented by the non-significance in p/T-ERK1/2 levels between L2000-CBD 
and VAirVPBS treatment groups in both PFC and NAcSh experimental analyses). Furthermore, 
similar to the previous GSK3β and Akt analyses, the lack of significant differences (albeit in the 
presence of a trend) between treatment groups following linalool administration in the control 
analysis suggests that linalool likely does not modulate ERK activity on its own; however the 
significant reduction of p/T-ERK levels following L2000-CBD treatment (compared to 
VAirCBD) in both PFC and NAcSh experimental analyses present the notion that linalool is 
potentially involved in allosteric modulation of ERK activity above a certain threshold level. In 
addition, the fact that L200-CBD treatment achieved significantly higher p/T-ERK1/2 levels in 
the NAcSh experimental analysis suggests that a dose-dependent attenuation of intra-NAcSh 
p/T-ERK1/2 levels resulting from olfactory exposure to increasing dosages of linalool may be a 
mechanism of action through which L2000-CBD treatment elicits its EE-potentiated anxiolysis 
observed previously in the behavioral assays. 
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4.4 JNK Protein Analysis 
 In a similar manner to the GSK-3β, Akt, and ERK protein analyses, no significant 
differences were found between treatment groups in the control analysis of either the JNK1 
isoform (p- JNK1: F(2, 11) = 0.7413, p = 0.4989 [figure 26A]; T- JNK1: F(2, 10) = 3.133, p = 0.0878 
[figure 26B]; p/T- JNK1: F(2, 10) = 0.1874, p = 0.8320; [figure 26C]) or JNK2 isoform (p- JNK2: 
F(2, 11) = 0.3476, p = 0.7139 [figure 26A]; T- JNK2: F(2, 10) = 2.752, p = 0.1116 [figure 26B]; p/T-
JNK2: F(2, 10) = 0.1727, p = 0.8439 [figure 26C).  
 Interestingly, when observing experimental analysis results within the NAcSh region as 
shown in figure 16D/E/F, significant differences between treatment groups were only found 
within the quantification of p-JNK1 (F(3, 19) = 3.827, p = 0.0267; figure 26D) and not within any 
other assessment of JNK1 protein levels (T- JNK1: F(3, 19) = 3.052, p = 0.0536 [figure 26E]; p/T- 
JNK1: F(3, 19) = 2.899, p = 0.0618 [figure 26F]) or JNK2 protein levels (p- JNK2: F(3, 19) = 2.872, 
p = 0.0634 [figure 26D]; T- JNK2: F(3, 19) = 2.779, p = 0.0693 [figure 26E]; p/T-JNK2: F(3, 19) = 
1.569, p = 0.2298 [figure 26F]). Post hoc analyses of p-JNK1 quantification revealed 
significantly increased expression levels by the VAirCBD group when compared to its respective 
VAirVPBS and L2000-CBD treatment groups (p ≤ 0.05). 
 ANOVA analyses of PFC region JNK quantification revealed a stark contrast to NAcSh 
region results (figure 16G/H/I). While non-significance was found between treatment groups 
when assessing T-JNK1 (F(3, 29) = 0.7696, p = 0.5204; figure 26H) and T-JNK2 (F(3, 29) = 0.5617, 
p = 0.6446; figure 26H), significant differences were found in the analysis of p-JNK1 (F(3, 29) = 
5.746, p = 0.0033; figure 26G), p/T- JNK1 (F(3, 29) = 6.781, p = 0.0013; figure 26I), p-JNK2 (F(3, 
29) = 4.885, p = 0.0072; figure 26G) and p/T-JNK2 levels (F(3, 29) = 3.824, p = 0.0201; figure 26I) 
between treatment groups. In both p-JNK1 and p-JNK2 post hoc analyses, the VAirCBD group 
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demonstrated significantly increased expression levels when compared to VAirVPBS and L2000-
CBD treatment groups (p ≤ 0.05); unlike p-JNK1 however, p-JNK2 analysis also demonstrated 
the L200-CBD group to exhibit significantly higher quantification than the L2000-CBD group (p 
≤ 0.05). Between p/T-JNK1 and p/T-JNK2 post hoc analyses however a pattern of significant 
differences between groups was found, with both the VAirCBD and L200-CBD groups 
expressing higher quantification levels compared to VAirVPBS and L2000-CBD treatment groups 
in their respective cohorts of analysis (p ≤ 0.05). 
Similar to previous molecular analyses, these findings from the JNK molecular assay 
suggest that the EE-potentiated anxiolysis elicited following L2000-CBD treatment observed 
previously in behavioral paradigms likely does not involve significant modulation of JNK 
activity from baseline levels (as presented by the non-significance in p/T-JNK1/2 levels between 
L2000-CBD and VAirVPBS treatment groups in both PFC and NAcSh experimental analyses). 
Furthermore, the non-significance (albeit in the presence of a trend) between treatment groups 
following linalool administration in all measures within the control analysis suggests that linalool 
likely does not modulate JNK activity on its own. However, the significant reduction of intra-
PFC p-JNK1/2 levels (as well as intra-PFC p/T-JNK1/2 levels) following L2000-CBD treatment 
(compared to VAirCBD) suggests the notion that linalool is likely involved in allosteric 
modulation of JNK activity above a certain threshold level. In addition, similar to patterns found 
in Akt and ERK molecular assays, the fact that L200-CBD treatment achieved significantly 
higher p/T-JNK1/2 levels in the PFC experimental analysis suggests that a dose-dependent 
attenuation of intra-PFC p/T-JNK1/2 levels resulting from olfactory exposure to increasing 
dosages of linalool may serve to be a component mechanism of action through which L2000-
CBD treatment elicits its EE-potentiated anxiolysis (observed in the behavioral assays). 
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Discussion 
 The findings of this thesis demonstrate for the first time the potential presence of the 
Entourage Effect between linalool and CBD in establishing a greater anxiolytic effect than their 
individual administrations. While previous studies had demonstrated the CBD and linalool’s 
modes of action through positive allosteric modulation of GABAARs and p-ERK 
downregulation, this study highlighted the importance of these mechanisms specifically 
following administration within the Nucleus Accumbens Shell (NAcSh) region. In light of the 
hypothesis set forth which proposed EE-potentiated anxiolytic effects present in both symptoms 
and biomarkers, these findings which demonstrate that significantly increased anxiolytic effects 
of the combinatorial treatment (linalool and CBD) observed in behavioral assays were negatively 
correlated with GABAAR inhibition and p-ERK activation, suggests that the linalool-CBD 
anxiolytic interaction dynamic likely involves a unique mediation of neuronal activity and 
cellular MAPK pathways not achieved by their individual administrations. 
Baseline Treatment Cohort: EE-Potentiated Anxiolytic Effects in Behavioral Assays 
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Regarding bright-space and fear-memory related anxiety, the EE-potentiated anxiolytic 
effect of linalool and CBD in comparison to their individual administrations was readily 
apparent. Within the light dark box and contextual fear conditioning assays, the combined 
2000µL linalool and 5ng/0.5µL CBD treatment yielded much greater decreases in anxiety 
symptoms than did their individual administrations (2000µL linalool or 5ng/0.5µL CBD), 
suggesting that the observed EE-potentiated anxiolysis is superiorly effective in alleviating 
bright-space and fear memory-related anxiety. These findings are consistent with those published 
currently in the literature surrounding the anxiolytic potential of individual cannabidiol (Fogaca 
et al., 2014; Gomes et al., 2010; Lemos et al., 2010; Long et al., 2010; Resstel et al., 2006) and 
linalool treatments (Coelho et al., 2018; Harada et al., 2018) in these test paradigms. 
Furthermore, in the context of the CFC behavioral assay, this EE-potentiated anxiolysis exhibited 
by the L2000-CBD treatment was present in both the acquisition and recall scenarios, suggesting 
that the treatment is potentially effective in both the prevention of anxiety stemming from fear 
memory consolidation and the recall of such fear-related memory events. When taking into 
account the observation that locomotor differences between groups were absent as documented 
by Linck et al. (2010) and Long et al. (2010) following acute linalool and CBD administrations 
respectively, this in turn presents the notion that this EE profile may uniquely affect the limbic 
region (known for affective processing) without altering motor cortex functionality (Ali et al., 
2015; Guimaraes, 2004). 
Interestingly, while the L2000-CBD treatment presented EE-potentiated anxiolysis within 
these behavioral test paradigms, the lesser linalool-CBD combination treatment of L200-CBD 
did not elicit significantly different freezing time compared to either of its component vehicle 
groups (VAirCBD or L200-VPBS) and only expressed significant differences to its VAirCBD 
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vehicle counterpart in the secondary bright-space anxiety measure of total transitions. Yet, 
despite this contrast in EE-potentiated anxiolysis between L200-CBD and L2000-CBD 
treatments, no significant differences were found between the two groups in all test paradigms—
suggesting the lack of a conclusive dose-dependent response in the combinatorial administration 
of linalool and CBD (with respect to comparisons between 200 μL and 2000 μL). These findings 
of non-significance but increasing trends of anxiolytic efficiency with greater linalool dosage 
administrations has been documented by Coelho et al. (2018), presenting the notion that there 
may be a moderate dose-dependent curve in linalool anxiolytic efficiency. 
The overall lack of significant differences between treatment groups when assessing 
social cognition measures within the social motivation and recognition test suggests that there is 
no EE-potentiation in social cognitive abilities or associated anxiety following linalool-CBD 
dual treatment. Although this observation stands in contrast to the finding established by Linck et 
al. (2010) whereby linalool induced greater social interaction time (equivalent to greater social 
motivation values), these findings align with the non-significance found from administration of 
CBD-alone treatments (Long et al., 2010; Malone et al., 2009). In addition, while an olfactory 
administration of linalool was used in the context of this thesis, Linck et al had employed 
intraperitoneal linalool administrations; given that Takahashi et al. (2011) had found linalool 
acetate to be essential in eliciting anxiolytic effects observed in the EPM test paradigm, this 
suggests that the interaction between linalool and its formed metabolites following systemic 
metabolism of pure linalool may be responsible for this difference in observed social behaviors. 
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Linalool-CBD combinations demonstrated anxiolysis in the EPM assay only following CUS 
exposure 
 Although results from the chronic stress cohort demonstrated significant differences 
between CUS-exposed VAirVPBS and L2000-CBD treatment groups in the EPM assay, this was 
not the case in the baseline cohort. Indeed, while the LDB and CFC assays suggested the 
presence of an EE-potentiated anxiolysis following L2000-CBD treatment, this phenomenon was 
not found in the EPM test anxiety measures within the baseline cohort as currently observed in 
the literature surrounding CBD and linalool’s individually observed anxiolytic effects (Bradley 
et al., 2007; Campos and Guimarães, 2008; Harada et al., 2018). It should be noted, however, 
that different modes of administration (intracranial versus intraperitoneal, dorsolateral 
periaqueductal gray versus NAcSh) as well as duration of drug administration (acute versus 
chronic) have been employed to achieve these results in the aforementioned studies; thus, 
significant differences between observed results and literature findings may stem from 
differences in testing methodologies. Furthermore, when taking into consideration studies 
incorporating intracranial infusion of CBD into brain regions within the mesolimbocortical 
pathway (PFC, hippocampus) and within closer anatomic proximity to the NAcSh (PFC), no 
significant differences were found in anxiety measures assessed in the elevated plus maze test 
and other open-space anxiety test assays (Hudson et al., 2019; Szkudlarek et al., 2019). 
 Another potential basis for these findings may be attributable to the notion that the EE-
potentiated anxiolysis of L2000-CBD attenuates different forms of anxiety to differing degrees, 
especially depending on the behavioral paradigm used; specifically, while this potentiated 
anxiolysis may be present in the reduction of bright-space and fear- memory anxieties as 
observed respectively in the LDB and CFC assays, it may not be as relevant in the context of 
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open-space anxiety assessed in the EPM assay. This line of inquiry has been supported by 
Miyakawa et al (2003), who found that rodent models expression of anxiety measures between 
the LDB and EPM tests were not always consistent—suggesting either differences in 
environmental conditions or measures of different forms of anxiety being the cause of this 
observed phenomenon (Takao and Miyakawa, 2006). Furthermore, even in the consideration of 
schizophrenic rodent models (C57BL/6J) where CBD treatment is proposed to have a significant 
reduction in anxiety, the same anxiolytic profile was not observed between the two tests 
following CBD treatment (Long et al., 2010; Schleicher et al., 2019).  
Taking into account the fact that post hoc analyses of open-field thigmotaxis (via 
center/total locomotion ratio assessments) conducted in the flumazenil and EPA challenge 
cohorts revealed the L2000-CBD group to yield significantly reduced open-space anxiety when 
compared to the VAirVPBS control group, this ultimately suggests that the non-significance within 
baseline cohort assessments involving EPM anxiety measures is likely attributable to a 
combination of differences in methodology and varying sensitivity between assays in assessing 
specific forms of anxiety—and that these variations in environmental conditions or sensitivity to 
such fluctuations which may play a role in the generation of non-significance essentially did not 
influence CUS-exposed models in the same manner.  
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GABAAR inactivation reversed EE-potentiated anxiolytic effects 
 
 
 
 
 
 
 
 Significant increases in LDB and CFC anxiety measures exhibited by L2000-CBD 
subjects following co-administration of the GABAAR antagonist flumazenil suggests that 
GABAAR activation is essential in the EE-potentiated anxiolysis induced through L2000-CBD 
treatment. While assessment of L2000-CBD effects is a novel venture, the lack of significant 
differences between control and flumazenil vehicle groups in these tested assays and flumazenil 
attenuation of BDZ-site agonist-induced anxiolysis have been documented in the existing 
literature (Clément et al., 2009; Herzog et al., 1996; Hussain et al., 2015; Rex et al., 1996). In 
addition, the observed lack of locomotor differences between co-administrations of flumazenil 
with L2000-CBD and L2000-CBD only treatments found here are in line with previous findings 
in the baseline cohort—reinforcing the notion that L2000-CBD treatment likely does not impair 
motor function, and thus flumazenil would not be expected to elicit any alternations in locomotor 
activity. Interestingly however, the assessment of OFT open-space anxiety introduced in the 
flumazenil challenge cohort demonstrated that while locomotor abilities of test subjects did not 
significantly differ between treatment groups, L2000-CBD treatment generated significantly 
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reduced open-space anxiety symptoms as evidenced by the significantly greater center/total 
locomotion percentage ratios in comparison to the VAirVPBS group. In addition, the significantly 
increased open-space anxiety exhibited by the L2000-CBD+flumazenil group when compared to 
the flumazenil-free L2000-CBD group counterpart suggests that GABAAR antagonism plays a 
key role in attenuating L2000-CBD induced open space anxiety in the OFT assay.  
 Delving further into the EE-potentiated anxiolysis presented in the LDB and CFC assays, 
it is important to mention that given the absence of significant differences between control 
vehicles and flumazenil treated control vehicles in conjunction with significantly increased 
anxiety exhibited by the L2000-CBD+flumazenil group (in contrast to its L2000-CBD group 
counterpart) in these two assays, this suggests that flumazenil attenuations of L2000-CBD 
anxiolysis may stem from mostly antagonist-exogenous compound interactions rather than 
antagonist-endogenous compound interactions. A plausible explanation for this phenomenon 
includes the possibility that flumazenil competitive inhibition of GABAARs following intra-
NAcSh administration in control vehicles induces changes in neuronal activity that are not 
significant enough to be translated to behavioral changes—but that in the presence of an 
increased number of neuronal populations being hyperpolarized due to L2000-CBD treatment, 
flumazenil antagonism of L2000-CBD induced molecular mechanisms is significant enough to 
translate into a reversion of observed behavior in L2000-CBD treated subjects.  
Given that the literature has documented the greatest change in GABA EC50 to be elicited 
by CBD following allosteric modulation at α2 subunit configurations (Bakas et al., 2017) and 
primarily for linalool at α1 subunit configurations (Kessler et al., 2014; Milanos et al., 2017), this 
differential modulation of GABAAR subunits provides support for EE-potentiated anxiolysis of 
L2000-CBD—and given that flumazenil has been found to primarily target α1/α2/α3/α5 subunit 
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configurations (Huang et al., 1998; Wieland and Lueddens, 1994), its administration and 
subsequent competitive inhibition at these sites would be expected to result in the behavioral 
observations seen in this experimental challenge cohort. This hypothesized mechanism of action 
would especially help explain the L2000-CBD induced reduced fear recall that was reversed by 
flumazenil treatment, as Schmitz et al. (2017) had demonstrated decreased hippocampal GABA 
levels to result in dysfunctional suppression of memory recall. Furthermore, in consideration of 
the connections between the olfactory bulb, the entorhinal cortex and hippocampus as previously 
mentioned (Christen-Zaech et al., 2003; Vanderwolf, 1992), this GABAAR-mediated anxiolytic 
theory provides a potential explanation for downstream effects elicited by activation of the 
olfactory system upon linalool inhalation. 
Although promising, further in-vitro investigations assessing co-administrations of 
linalool and CBD on GABA EC50 however are required to substantiate correlational claims 
between potential synergism surrounding EE-potentiated GABA current induction and the 
antagonistic effects elicited by flumazenil on the molecular and systems level. 
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Activation of p-ERK reversed EE-potentiated anxiolytic effects 
 
 
 
 
 
 
\ 
 The attenuation of EE-potentiated anxiolytic effects following EPA coadministration 
observed in the EPA challenge cohort suggests that p-ERK activation is a key regulator of 
mechanistic pathways utilized by L2000-CBD treatment to elicit its observed anxiety reduction 
in test subjects. Non-significance findings between control vehicles and EPA-treated vehicles in 
these assays are representative of the currently established literature (Einat et al., 2003; Sierra-
Fonsecaet al., 2019). Furthermore, regarding interactions between p-ERK and CBD, Hudson et 
al. (2019) had found (utilizing the same mode of acute EPA administration via intra-vHipp) that 
EPA administration—and consequently, increased p-ERK expression—was able to significantly 
attenuate the anxiolysis induced by the combinatorial administrations of THC and CBD within 
the LDB and CFC [acquisition] assays. Lastly in line with previous test cohorts, no significant 
differences in locomotion was detected between groups, suggesting the lack of locomotor 
impairments as a result of EPA treatment and the confirmation of no potential confounder in 
subsequent assays as a result of locomotor differences.  
This finding of non-significance in locomotor differences is particularly interesting in 
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light of the fact that co-treatment of intra-cranial EPA and L2000-CBD resulted in the 
elimination of OFT open-space anxiolysis, which was found present following L2000-CBD 
treatment as shown by stark contrasts in center/total locomotion (%) performance—
demonstrating a similar pattern of results to the OFT anxiety assessment conducted by Hudson et 
al. (2019). Although Hudson and authors utilized group comparisons which are not directly 
comparable with the results in this study (as THC+CBD and EPA+THC+CBD groups were used 
as opposed to L2000-CBD and L2000-CBD+EPA groups), the significantly increased open-
space anxiety observed following the addition of EPA to THC+CBD combination treatments is 
especially notable due to the fact that it provides a comparative assessment p-ERK effects on 
EE-potentiation; as despite these obvious differences in EE combination components (CBD & 
THC versus CBD & linalool), the study provides at least a rudimentary foundation to refer to in 
the pursuit of correlations between p-ERK levels and novel EE combinations, such as the one 
between CBD and linalool explored in this thesis. In addition, while elevated p-ERK expression 
is known to result in downstream gene expression alterations over a long-term basis, the acute 
findings in this thesis and those made by Hudson et al. (2019) suggests that the observed 
attenuations in anxiety likely stems from fast-acting targets downstream of increased p-ERK 
activation. This aligns with observations made in a review conducted by Peng et al. (2010) 
highlighting the correlation between increased p-ERK and two receptors involved in long term 
potentiation (LTP) memory receptors, the NMDA and AMPA receptors. Given the results in the 
CFC assay which involves fear memory formation and subsequent recall, the increased freezing 
time exhibited by test subjects who received co-administrative L2000-CBD and EPA treatment 
suggests that the observed EE-potentiated anxiolysis likely involves either inactivation or fast-
acting downregulation of these target receptors and their subsequent synaptic alterations. 
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 As previously mentioned, correlations between ERK activation and linalool have also 
been studied by Caputo et al. (2016; 2017; 2018) who discovered through in-vitro assays that 
linalool was able to inhibit ADCY1, p-ERK and PKA expression within the SH-SY5Y cell line. 
PKA has been shown to be essential in a host of cellular activities, including the regulation of 
NMDARs and stimulation of downstream CREB-dependent transcription, both of which are 
implicated in memory formation (Impey et al., 1998). ADCY1, which catalyzes the formation of 
cAMP and thus is innately involved in the subsequent activation of PKA, has been found 
upregulated in the nucleus accumbens of subjects with fear memory and associated anxiety (Du 
et al., 2019); even more relevant in its study is the discovery that the lack of ADCY1 has been 
directly linked to lowered sustainability of contextual memories, such as those acquired in the 
CFC assay (Shan et al., 2008). Given the imaging findings of ERK and PKA co-activation during 
LTP structural changes by Tang and Yasuda (2017) as well as the fact that ERK-mediated 
signaling is a downstream target of ADCY1 activation, artificial p-ERK activation via EPA 
administration provides a plausible explanation for the loss of behavioral effects previously seen 
following linalool administration. 
 While these initial findings suggest ERK phosphorylation levels to be vital in regulating 
EE-potentiated anxiolysis induced by L2000-CBD, it should be mentioned that the effects 
observed following EPA administration undoubtedly involves ERK interaction with other 
proteins and their associated signaling pathways, such as the PI3K (phosphoinositide 3-kinase) 
pathway known to be implicated in crosstalk activity as well as regulation of the MAPK/ERK 
pathway (Steelman et al., 2011; Won et al., 2012). Thus, while these initial findings provide 
insight into the gross relations between EPA administration and associated reductions in EE-
potentiated anxiolytic efficiency, further investigations studying associated crosstalk proteins 
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(alone and in tandem) are required to elucidate the exact molecular mechanisms underlying these 
behavioral correlations. 
Chronic Unpredictable Stress: EE-Potentiated effects in behavioral assays 
 
 
 
 
 
 
 
 
 
 
Utilizing the novel chronic unpredictable stress (CUS) protocol established by former 
laboratory researcher Dr. Justine Renard, no significant differences in locomotor activity were 
found while significant differences were observed between treatment groups in the light dark box 
and three-chamber social interaction test that suggest the presence of EE-potentiated effects. 
Although employing different variants of the CUS protocol, various studies have reported similar 
findings of relatively equal locomotor activity but increased perceived anxiety by CUS-exposed 
subjects when compared to non-stressed controls (Kaufmann and Brennan, 2018; Monteiro et al., 
2015). Interestingly, the inability of L2000-CBD to reverse the observed anxiety in the CUS-
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VAirVPBS group stands in contrast to these literature findings and previous results of open-space 
anxiolysis observed between L2000-CBD and VAirVPBS groups in the challenge cohorts. While 
longer duration (4-8 weeks) and variations in CUS protocols, as well as use of mouse models 
may explain the differences in OFT results between those found in the literature (Kaufmann and 
Brennan, 2018; Monteiro et al., 2015) and this study, discrepancies concerning significant 
differences comparing L2000-CBD and VAirVPBS vehicle groups between challenge cohorts and 
the chronic stress cohort are very likely to be attributable to vast variations in animal handling 
duration prior to testing. Specifically, the fact that the L2000-CBD and VAirVPBS groups 
experienced increased handling durations (an extra 14 days prior to testing due to CUS protocol 
procedures) compared to their equivalents in the challenge cohort likely resulted in a significant 
reduction of baseline anxiety levels; combined with the fact that the OFT assay was also 
conducted relatively early on in the testing timeline following minimally stressful behavioral 
assays (SA and NOR), it is entirely plausible that the reduced baseline anxiety levels remained 
present during open field testing—effectively attenuating significant differences in open-space 
anxiety previously observed in the challenge cohorts between the L2000-CBD and VAirVPBS 
groups. 
 Studies employing CUS protocol variants have also documented chronically stressed 
rodent models exhibiting significant increases in anxiety symptoms compared to their non-
stressed control counterparts within the light dark box (Beery et al., 2012; Cancela et al., 1995; 
Nasca et al., 2015) and elevated plus maze behavioral assays (Kaufmann and Brennan, 2018; 
Monteiro et al., 2015; Rudyk et al., 2019). These established literature findings are consistent 
with the observed anxiety measures in the LDB test, where a pre-planned t-test comparison 
between VAirVPBS and CUS-VAirVPBS groups revealed the non-stressed group to exhibit 
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significantly greater exposure in the light compartment. Interestingly however, this correlation 
between vehicle groups was only moderate in nature within the EPM assay (t(14) = 1.872, p = 
0.082; data not shown); this reduction of stress model efficiency may be attributable to the fact 
that the employed CUS protocol was shorter in nature (2 versus 3 weeks exposure to CUS in the 
aforementioned studies) and that the EPM test was conducted 14 days after cessation of the CUS 
protocol (designated last in the battery of tests) in comparison to the LDB test which was carried 
out 7 days following protocol termination.  
Despite this lag in testing, the L2000-CBD treatment was found to result in significantly 
reduced anxiety within both the LDB and EPM assays, as was observed with the significantly 
increased exploration in the light compartment and open arms exhibited by the CUS-L2000-CBD 
group in comparison to its CUS-VAirVPBS counterpart—suggesting that in the context of chronic 
stress conditions, L2000-CBD treatment may be effective in alleviating both augmented levels of 
bright-space and open-space anxieties. When considering the establishment of EE-potentiated 
anxiolysis between L2000-CBD and its vehicle counterparts (VAirVPBS, VAirCBD, L2000-VPBS) 
in the baseline cohort as well as assessing the similarities in observed behavioral phenomenon 
between chronic control and experimental groups, the inference of EE-potentiation within these 
chronic stress behavioral assays stands to be of merit. While Campos et al. (2013) and 
Saiyudthong et al. (2016) have demonstrated individual administrations of CBD or linalool to be 
effective in reversing chronic stress-induced alterations observed in anxiety and depression 
behavioral assays respectively, their use of daily intraperitoneal administrations starkly contrasts 
the single pre-test intracranial drug infusions employed within this thesis. Thus, to date, the 
persistence of conceivable EE-potentiated anxiolysis within chronic stress settings remains a 
plausible line of inquiry. 
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 Although there were clear differences in the degree of anxiety symptoms presented 
between CUS-exposed and non-stressed treatment groups in anxiety assessments, results from 
pre-planned t-test comparisons (data not shown due to non-significance) and ANOVA analysis 
of SA and NOR tests suggest that working and long-term memory were not impaired in 
chronically stressed vehicle models. The non-significance found in these memory cognition tests 
are consistent with findings from Sadowski et al. (2009), Bowman et al. (2006) and Foyet et al. 
(2017), with the latter employing a CUS protocol most similar in nature to the one used in this 
thesis. However, despite the lack of memory impairments in CUS rat models, CUS-VAirVPBS 
subjects were found to exhibit significantly lower SMI and SRI values versus non-stressed 
VAirVPBS in stages 2 and 3 respectively of the social motivation and recognition test. This 
deficiency in both social motivation and recognition is consistent with the existing literature 
assessing effects of chronic stress on equivalent social interaction measures between non-
stressed and chronically stressed vehicle groups (Van der Kooij et al., 2014; 2014a; Zain et al., 
2019).  
The fact that no apparent memory deficits were found between groups within the chronic 
stress cohort suggests that the significant SMI and moderate SRI deficits presented by CUS-
exposed control subjects (in comparison to stress-free VAirVPBS subjects) likely stem from 
affective processing dysfunction rather than diminished memory capabilities. This finding is 
particularly interesting in light of the literature surrounding the impact of chronic stress on 
different brain regions. For while the hippocampus, which is well-known for its involvement in 
the recall of episodic memory (Ross et al., 2018), can endure several weeks of chronic stress 
before undergoing structural alterations (Mcewen, 2004), atrophy of dendrites within the PFC 
has been found to result after a one week duration of CUS or even a single exposure event to 
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such stressful conditions (Brown et al., 2005; Izquierdo et al., 2006). Given that the PFC is one 
of the key components within the mesolimbocortical pathway involved in affective processing 
and executive decision making, structural atrophy of this region—and in particular, degradation 
of its connections to the amygdala—would help explain the decreased sociability and social 
novelty exhibited by CUS-treated vehicle groups, as the loss of PFC regulation over the 
amygdala would provide a likely explanation for this observed phenomenon in the absence of 
memory impairments (Liu et al., 2020).  
 Given that L2000-CBD treatment was able to reverse SMI and SRI deficits to a moderate 
and significant degree respectively in CUS-treated subjects, this in turn suggests that the 
consequentially inferred EE-potentiation likely involved altered activation of the PFC and 
associated brain regions in eliciting the changes in observed behavioral phenomena. Taking into 
consideration that CBD and linalool have both been well documented to act on 5-HT1A and 
GABAA receptors which are essential in the regulation of neuronal activity, the fact that vast 
numbers of these receptors reside within brain regions such as the PFC and amygdala lends 
credence to potential mechanisms of action underlying observed EE-potentiated effects (Albert 
et al., 2014; Ghosal et al., 2017; Liu et al., 2014). Ultimately however, further investigations will 
need to be pursued to address this mechanistic line of inquiry pertaining to EE-potentiation and 
brain region activation. 
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Molecular Profiles underlying EE-potentiated Anxiolysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 When assessing the possibility of an EE-potentiated anxiolysis between CBD and linalool 
(2000μL), it is important to not only observe effects on a systems behavioral level but also on the 
molecular level to potentially determine any underlying mechanisms that may correlate between 
the two phenomena. While certain trend patterns were observed, the lack of significant 
differences in all p/T protein expressions between VAirVPBS and the linalool vehicles (L200-VPBS 
and L2000-VPBS) suggests that odorous linalool administration on its own, whether at the 200 or 
2000μL dosage, does not yield notably different protein activation profiles compared to vehicle 
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conditions. Notably, this molecular observation correlates with the relative lack of significant 
differences between linalool vehicles and the VAirVPBS treatment group found in the majority of 
one-way ANOVA analyses evaluating behavioral assay results. 
 In contrast, while no significant differences in p/T protein expression were found 
between the VAirVPBS and L2000-CBD groups, the VAirCBD group presented significantly 
different protein levels compared to the L2000-CBD as shown in Figure 31B (these differences 
are highlighted in red within the summary table). When considering the results from behavioral 
assays conducted, this in turn suggests that linalool likely acts in a manner that either 1) interacts 
with CBD at the receptor level via allosteric modulation or receptor-complex formation, 2) alters 
the effects of downstream signaling originally induced by CBD, 3) targets proteins and their 
associated pathways outside the scope of the current molecular investigations or 4) results in a 
combination of all these potential mechanisms. While addressing these mechanistic potentials 
however, the results of each protein will be discussed in relation to one another as these proteins 
ultimately interact with one another in either a direct or indirect manner. 
 Through in-vivo investigations utilizing behavioral assays following the knockdown of 
GSK3β, Crofton et al. (2017) demonstrated that decreased GSK3β expression was correlated 
with reductions in anxiety-like behavior in rodent models. In relation to the thesis molecular 
findings, this is particularly interesting given the fact that while there were no significant 
differences found in p/T-GSK3β expression between the L2000-CBD or L2000-VPBS treatment 
and the VAirVPBS group, the VAirCBD group exhibited significantly increased levels in 
comparison to both the VAirVPBS group and L2000-CBD treatment groups. The increase in p/T-
GSK3β expression following VAirCBD administration and the subsequent decline in following 
the introduction of linalool into CBD treatment formulations suggests that linalool likely acts in 
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some manner as an inhibitor of GSK3β phosphorylation—in turn suggesting that L2000-CBD 
treatment achieves behavioral anxiolysis by inducing molecular changes within both the PFC and 
NAcSh that either utilize a GSK3β-independent pathway and/or target downstream GSK3β 
effectors.  
The results of the VAirCBD treatment group are supported by the current advancements in 
literature, which document CBD to noticeably increase p-GSK3β expression (Fogaça et al., 
2014; Libro et al., 2016; Vallée et al., 2017); furthermore, Libro et al. (2016) and Renard et al. 
(2016) had specifically noted correlations between Akt activation and observed p-GSK3β levels. 
The findings of Libro et al. (2016), who utilized in-vitro assays of mesenchymal stem cells and 
found CBD administration to result in increased expression of p-GSK3β and p-Akt, provide 
greater support for the observed increases in these respective phosphorylated/total protein levels 
following VAirCBD administration; unfortunately however, due to lack of specifications 
regarding Ser- and Thr-residue phosphorylation, site-specific correlations cannot be referenced 
to. Interestingly however, Renard et al. (2016), whom utilized the same intra-NAcSh delivery of 
CBD employed in this thesis, discovered significantly decreased p/T-GSK3β levels concurrent 
with significantly decreased p/T-Akt levels in CBD-treated versus vehicle-treated AMPH-
sensitized rats, further supporting the findings of Libro et al. (2016). This exception to the 
classical antagonistic relationship between the two proteins has in fact been documented by 
Beurel et al. (2015), who noted that Akt serine-phosphorylation does not result in absolute 
inhibition of GSK3 activity—and that in some cases such as the combined inhibitory 
phosphorylation of AMP-activated kinase (AMPK) by GSK3 and Akt, the two proteins can work 
in a cooperative rather than antagonistic manner. While the AMPH-sensitization of rat models 
used by Renard and authors does not provide an ideal comparison to the models utilized in this 
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thesis, the combined findings of Libro et al. (2016), Renard et al. (2016) and Beurel et al. (2015) 
nonetheless suggest that CBD may elicit its effects through a mechanism of action that bypasses 
the Akt/GSK-3 signaling pathways, providing an interesting finding that contrasts traditional 
associations of inversely-correlated protein activity between GSK3β and Akt (Sani et al., 2012), 
as well as a potential component mechanism of action through which L2000-CBD elicits EE-
potentiated anxiolysis.  
In contrast to the documented increase in inhibition of GSK3β following CBD treatment, 
the molecular literature surrounding linalool focuses on Akt, and thus in extension, its 
downstream regulation of GSK3β. An in-vitro study conducted by Pan and Zhang (2019) 
observed in a clear-cut manner that linalool exposure (μM range) resulted in a dose-dependent 
decrease in both phosphorylated PI3K and Akt, while expression of non-phosphorylated PI3K 
and Akt remained unchanged. Although no significant differences between linalool-vehicles and 
the control condition were observed in-vivo in this thesis when assessing either p/T-GSK3β or 
p/T-Akt, the results of Pan and Zhang help to explain the significant reduction in both protein 
expressions observed in the L2000-CBD treatment group (when compared to the VAirCBD 
group)—ultimately suggesting that linalool may antagonize CBD-mediated effects on GSK3β 
and Akt through inhibition of the PI3K/Akt pathway. Interestingly however, Rodenak-Kladniew 
et al. (2018) had found that when employing a higher concentration of linalool in-vitro (in the 
range of mM rather than μM), there was a negative correlation between phosphorylated Akt 
levels and linalool concentration trending towards non-significance between the vehicle and 2.0 
mM (highest dosage)  linalool exposure groups; nonetheless, 1.0 and 1.5 μM of linalool 
concentration exposures were sufficient to elicit significant declines in phosphorylated Akt levels 
compared to control conditions. While this discrepancy in findings between the two in-vitro 
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studies may be attributable to differences in the cell line utilized (OECM-1 vs. HEPG2 
respectively), it potentially proposes the fascinating concept of a biphasic effect profile for 
linalool on the molecular level that presents at specific dosages and via particular administration 
routes. Consequently, given that these referenced studies involved direct contact of pure linalool 
with cell cultures, further investigation utilizing intraperitoneal injections of linalool with rat 
animal models can help clarify whether this dose-dependent response is replicable within in-vivo 
models and in turn confirm whether there are significant differences in molecular activity 
profiles between odorous and intraperitoneal exposures to linalool. 
When analyzing the potential mechanistic pathways through which these proteins elicit 
their effects, it is important to consider the duration of treatment administration (which was 
acute, or at most arguably sub-chronic in nature). Thus, while alterations in GSK3β and Akt 
activity are known to induce long-term changes through nuclear localization of downstream 
target effectors and subsequent changes in mRNA production (Steelman et al., 2011), short-term 
changes are crucial to consider in the context of acute/sub-chronic treatment protocols. A 
relatively acute mode of action to consider is the ability of GSK3β to inhibit NMDAR-dependent 
LTP and induce NMDAR-dependent LTD (long-term depression) as demonstrated by Peineau et 
al. (2007); Peineau and authors had found in particular that inhibition of GSK3β during LTP via 
activation of the PI3K-Akt pathway prevented synapses from undergoing LTD for up to 1 hour. 
In addition, Leibrock et al. (2013) had found that while Akt2 knockout mice displayed increased 
anxiety, they did not present cognitive impairments. Taking these two findings together into 
consideration, it is plausible that reduced Akt activation—and consequently increased GSK3β 
and LTD processes—observed in the L2000-CBD group resulted in decreased NMDAR activity 
and associated NMDAR-dependent LTP that disrupted the formation of synaptic strengthening 
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that would otherwise augment the consolidation of anxiety-related affections and associated 
memories in anxiety assays (most notably the CFC test). This hypothesized, fast-acting 
NMDAR-dependent mode of action itself is substantiated by studies demonstrating both 
decreased depression and anxiety following NMDAR antagonism (Holubova et al., 2014; Vose 
and Stanton, 2017). Given the roles of PFC and the NAcSh in working memory and associated 
affective processing respectively, these observed findings of reduced p/T-GSK3β and p/T-Akt 
levels elicited by L2000-CBD treatment in comparison its vehicle counterparts present a case for 
acute resilience to environmental stressors, providing in turn an interesting line of inquiry to 
pursue in further investigations assessing mechanisms underlying EE-potentiated anxiolysis 
induced through L2000-CBD treatment. 
In addition to GSK3β and Akt expression levels, ERK and JNK proteins have been found 
to be integral in the modulation of affective processing; specifically, their increased activation 
has been associated with increased anxiety-like behavior (Ailing et al., 2008; Hollos et al., 2018; 
Mohammad et al., 2018; Pucilowska et al., 2015; Xiang et al., 2017; Zhao et al., 2017). When it 
comes to the individual EE-components, CBD exposure (20μM) to in-vitro cultures involving 
glioblastoma cells has been documented by Ivanov et al. (2017) to result in significantly 
upregulated levels of p-JNK1/2, while downregulating p-ERK1/2 and p-Akt expression; 
however, these p-ERK molecular results stand in contrast to the findings of McAllister et al. 
(2011) who observed CBD treatment (1.5μM) to significantly increase p-ERK expression while 
not affecting T-ERK expression in in-vitro cultures of human breast cancer cells (MDA-
MB231). While this contrast in findings may be explained by the differing nature of the cells 
used, the change from upregulation to downregulation of p-ERK1/2 following an increase from 
1.5 to 10 μM CBD exposure can potentially be attributed to the biphasic effects of CBD 
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observed by Gallily et al. (2015) following intraperitoneal administration. Specifically, the 
discovery that this biphasic effect was found present in serum TNFα levels (u-curve correlation 
between increased CBD dosage and serum TNFα expression) provides support for this potential 
mechanism of action, as TNFα is capable of activating ERK and JNK kinases (which would in 
turn phosphorylate ERK and JNK to their active forms) (Sabio and Davis, 2014). Furthermore, 
this may not only help explain the discrepancy in molecular activation profiles between the 
studies conducted by McAllister et al. (2011) and Ivanov et al. (2017), but could also provide a 
basis for differences in p-ERK activation following bilateral intracranial infusions utilized in this 
thesis and by Hudson et al. (2019)—as Hudson and authors had documented no significant 
differences in p-ERK expression between control and CBD treatment groups following 100 
ng/0.5 μL CBD administration (in comparison to the 5 ng/0.5 μL used in this thesis). 
Collectively, these findings not only highlight the potential for biphasic effects on the molecular 
level following CBD administration but also bring to the forefront possible considerations of 
TNFα being a key component in CBD’s modulatory effects on affective processing. 
 Contrasting the observed increase in p-ERK and p-JNK following VAirCBD 
administration, the addition of linalool to CBD formulations was shown to elicit a moderate 
dose-dependent decrease in p-ERK and p-JNK, with a significant reduction being observed 
following the addition of 2000μL linalool as represented by the L2000-CBD treatment group. 
These reductions in p-ERK and p-JNK are consistent with the current advancements in literature 
regarding the molecular effects of linalool administration (Caputo et al., 2018; Gunaseelan et al., 
2017). Closer examination reveals that Gunaseelan et al. (2017) recorded in particular the 
inhibition by linalool of UVB-induced (ultraviolet B rays) ROS formation and associated UVB-
induced phosphorylation of ERK and JNK proteins, whilst also inhibiting the formation of 
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biomarkers including TNFα (presenting TNFα-mediated inhibition of ERK and JNK pathways as 
a combined target for linalool + CBD treatment). While UVB-induced ROS was evidently not 
employed in this thesis, the key cellular event of ROS formation that leads to increased levels of 
p-ERK and p-JNK has been observed to occur in animal models following acute (≤ 1 hour) or 
chronic stress exposure (Huber et al., 2017; Nadeem et al., 2006; Zafir and Banu, 2009). As a 
result, these findings correlating ROS activity and decreased p-ERK and p-JNK expression 
following linalool exposure are arguably applicable to the thesis molecular observations, as these 
protein analyses were ultimately conducted following acute/sub-chronic stress exposures of 
rodent models. 
 Expanding on the work of Caputo and authors, in addition to inhibitions of p-ERK in the 
SH-SY5Y neuroblastoma cell line, studies conducted (2016; 2017; 2018) had shown that 
ADCY1 and PKA expression were also reduced in SH-SY5Y cells following linalool 
administration. Given that the activation cascade of ADCY1/cAMP/PKA leads to the initiation 
and maintenance of CREB alterations on the genomic level that are instrumental in the prognosis 
of mood disorders (Dwivedi and Pandey, 2008) as well as the fact that PKA activity has shown 
to be crucial in initiating neurite extension (Sánchez et al., 2004), some of the contributory 
effects of linalool towards EE-potentiated anxiolysis may be attributable to the previously 
mentioned regulation of LTP/LTD events in affective formation and processing. The linalool-
induced downstream modulation of PKA activity is particularly interesting to note given that in-
vitro studies conducted by Poisbeau et al. (1999) demonstrated that PKA activation in adult 
hippocampal neurons decreased GABAAR current amplitudes, providing a correlation between 
the findings of Caputo et al. (2016; 2017; 2018) and the significantly reduced anxiolysis 
exhibited by the L2000-CBD+flumazenil in the flumazenil challenge cohort. Altogether, these 
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studies highlight a mechanism of action unique to linalool that potentially differentiates the lack 
of anxiolysis observed following VAirCBD treatment from the presence of EE-potentiated 
anxiolysis following L2000-CBD treatment. It is interesting to note however that while 
significant differences between treatment groups were present in regard to p/T-JNK1/2 and p/T-
ERK1/2 levels, these differences were relatively region-specific. Increasing dosages of linalool 
exposure beginning with the linalool-free VAirCBD treatment led first to reductions in PFC p/T-
JNK1/2 levels, with even greater dosage exposure of 2000 μL linalool yielding reductions in 
both the PFC and NAcSh regions (when compared to VAirCBD group data); furthermore, p/T-
ERK1/2 levels exhibited by VAirCBD and L200-CBD groups were only significantly higher than 
those observed following L2000-CBD treatment in the PFC, and not the NAcSh region. Given 
that the drug delivery methods did not include intra-PFC administrations, these unique patterns 
of phosphorylation suggest a few inter-region mechanisms of interest including NAcSh-mediated 
inhibition of PFC MAPK/ERK signaling and an associated PFC-mediated reciprocal inhibition 
of NAcSh MAPK/ERK signaling at higher doses of linalool (2000 μL)—both of which are 
reflective of the GABAergic and glutamatergic connections between the two structures of the 
corticostriatal pathway. 
 Altogether, these studies assessing the individual effects of CBD and linalool on ERK 
activity propose a variety of mechanisms which may underlie correlations between 
phosphorylated ERK levels and the EE-potentiated anxiolysis observed in the baseline cohort, 
including CBD’s attenuation of TNFα levels, linalool’s reduction of ROS formation and PKA 
activation (Caputo et al., 2016; 2017; 2018; Gunaseelan et al., 2017; Sabio and Davis, 2014)—all 
of which have been described to result in decreased ERK activation. In addition, studies have 
demonstrated that GSK3β and ERK activity are inversely correlated, with ERK-mediated 
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inhibition of GSK3β activity being noted to particularly involve Akt activation (Pal et al., 2017; 
Wang et al., 2006). This inverse correlation between the two proteins helps to further explain the 
significant differences in molecular activation between the VAirVPBS and L2000-CBD baseline 
cohort groups, as the latter has been documented to uniquely involve the inhibition of ERK, and 
consequently non-inhibition of GSK3β through direct upstream PKA modulation in a linalool-
dependent manner whilst antagonizing CBD-mediated effects on GSK3β and Akt through 
PI3K/Akt pathway inhibition as described previously (Caputo et al., 2016; 2017; 2018; Pan and 
Zhang, 2019). Although western blot analysis of EPA challenge cohort data is required to 
confirm this interpretation, when considering these literature findings in conjunction with the 
results of reduced THC+CBD treatment anxiolysis following EPA co-administration in the study 
conducted by Hudson et al. (2019) and the attenuation of L2000-CBD anxiolytic efficacy when 
concurrently administered with EPA found in this study, the combined results of baseline cohort 
molecular analysis and EPA challenge behavioral analysis ultimately suggests that ERK protein 
activation serves as a likely antagonist of L2000-CBD mechanistic interactions that result in EE-
potentiated anxiolysis.  
While these proposed individual and concerted mechanisms of action for GSK3β, Akt, 
ERK and JNK provide insight into the generation of EE-potentiated anxiolysis, it is also 
important to consider the influence of these proteins on cell-surface receptor targets—in 
particular the GABA-A receptor, to address potential correlations between systems-level, 
receptor-level and intracellular activity present in the flumazenil challenge cohort data. 
Interestingly, GABAAR activity has been found to be negatively correlated to GSK3β activity 
through a D2-receptor mediated suppression mechanism (Beurel et al., 2015; Li et al., 2012). 
Furthermore, this suppression mechanism appears to be a product of a larger signaling cascade 
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involving Akt, termed the Akt/GSK3β signaling cascade (Beaulieu et al., 2007; Li et al., 2012). 
Although these literature findings documenting the collective inhibitory regulation of Akt and 
GSK3β on GABAAR activity correlate with p/T-Akt data following L2000-CBD treatment 
observed in this thesis, there exists lack of a significant increase in p/T-GSK3β following L2000-
CBD treatment. While this prevents a complete correlation from being established between these 
literature findings and the molecular data observed in this thesis, the exact mechanisms of action 
through which the Akt/GSK3β cascade modulates GABAAR activity—whether it be through 
direct modulation of phosphorylation sites or downstream effectors—remains unclear. In light of 
this complexity and the research conducted by Beurel et al. (2015) detailing that certain GSK3β 
protein complexes may be unaffected by inhibitory serine-phosphorylation, while the effects of 
the Akt/GSK3β signaling cascade may not be directly correlated to observed thesis data, the 
cascade mechanism presents nonetheless an interesting line of inquiry to pursue in investigating 
the relationship between these proteins, the GABAA receptor and the EE-potentiated anxiolysis 
found following L2000-CBD treatment in the baseline cohort. 
In addition to Akt and GSK3β, the two MAPK proteins—ERK and JNK—have also been 
found to impact GABAAR activity. Through in-vitro investigations using the HEK293 cell line, 
Bell-Horner et al. (2006) demonstrated that an ERK phosphorylation site (T375) on the GABAA 
receptor was essential in facilitating ERK-mediated inhibition of GABAAR activity; furthermore, 
administration of UO126 (inhibitor of MEK1/2, which is an upstream activator of ERK) resulted 
in the reduction of ERK phosphorylation/activation and consequently yielded increased 
GABAAR peak current amplitudes. Supporting this finding is the in-vitro research published by 
Brady et al. (2018), where enhancement of GABAAR activity via application of the GABAAR 
agonist muscimol resulted in delayed ERK activation. Interestingly, GABAAR agonism via 
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muscimol administration was also found to affect JNK pathway activity (Ma et al., 2016); a 
deeper investigation specifically revealed that increased GABAAR activity as a result of GABA 
or muscimol treatment resulted in significantly reduced JNK1/2 signaling activity compared to 
controls and that subsequent inhibition of GABAAR activity restored JNK1/2 activity.  
Collectively, these in-vitro studies (Bell-Horner et al., 2006; Brady et al., 2018; Ma et la., 
2016) demonstrate an opposing relationship between GABAAR activity and the two MAPK 
proteins, ERK and JNK, which help to explain the significant decrease in p/T-ERK and p/T-JNK 
levels exhibited by the L2000-CBD group when compared to the VAirVPBS group in the baseline 
cohort and the corresponding differences in anxiolysis achieved by the two treatments. Lastly, 
although western blot analysis of the flumazenil challenge cohort is required to substantiate these 
interpretations, the correlation in findings between GABAAR activity, molecular profiles 
supported by the literature and anxiolytic differences between the L2000-CBD and control 
treatment groups suggests that flumazenil—which effectively attenuated the anxiolytic efficiency 
of the L2000-CBD treatment to vehicle levels—and consequently GABAAR antagonism are able 
to effectively reverse EE-potentiated anxiolysis elicited by L2000-CBD treatment. 
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While these collections of studies help to elucidate the EE-potentiated mechanism of 
CBD-linalool treatments, conclusive interpretations remain relatively difficult to establish 
without further investigation. A primary concern is that although these fascinating results and 
associated mechanisms may show merit, the current thesis findings and supporting studies 
discussed can only at best establish a correlational impact between olfactory nervous system 
activation and downstream effects on the entorhinal cortex and hippocampus (and thus episodic 
memory formation). For while the literature reports that lavender oil has been shown to modulate 
autonomic nerve activity and relevant signaling pathways in the CNS (Koulivand et al., 2013), 
without electrophysiological investigations assessing hippocampal activity following linalool 
administration, only assumptions can be made between behavioral phenomena, biomarker levels 
and associated brain activity. 
There also remain systems-level and molecular-level complexities to consider in the 
analysis of behavioral and molecular observations following L2000-CBD treatment. On the 
systems-level, given that the NAcSh forms an integral component of the greater 
mesolimbocortical pathway and that the interactions between the PFC, amygdala and nucleus 
accumbens as a result of their circuit connections have been deemed essential in affective 
processing (Jackson and Moghaddam, 2001), this suggests that the observed molecular profiles 
within the PFC region played a key role in producing the behavioral outcomes recorded 
following treatment exposures. However, the manner in which mesocorticolimbic regions such 
as the PFC and VTA respond to molecular changes and subsequent reciprocal regulation of 
associated brain regions—notably in conjunction to the NAcSh—following L2000-CBD 
administration remains unclear. As mentioned in section 1.2.3, this consideration of associated 
mesocorticolimbic regions is especially important when it comes to the VTA, as there exists a 
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prominent feedback system between the NAcSh and VTA that regulates dopaminergic activation 
of the NAc (and associated structures) as described previously; in addition, VTA glutamatergic 
inputs have shown to play a regulatory role of intra-NAc GABAergic interneurons, which 
subsequently in turn modulate the inhibitory projections/ability of the NAc (Qi et al., 2016). 
On the molecular level, an important complexity to consider is that significant differences 
in Akt protein expression were solely found in relation to the Ser473—and not Thr308—site of 
Akt. This is particularly interesting since Thr308 site-specific phosphorylation was originally 
thought to be conclusive evidence of Akt activation—and yet emerging evidence suggests that 
not only can the two sites regulate one another, but that downstream effects differ depending on 
site-specific phosphorylation and that both sites are required to be phosphorylated for full 
activation of Akt (Vadlakonda et al., 2013; Yung et al., 2011). Ultimately, further investigations 
incorporating the use of electrophysiology, as well as specifically disconnection studies between 
NAcSh and these associated brain regions following the use of protein-specific inhibitors 
(including phosphorylation site-specific activators/inhibitors in the case of Akt) may help to 
elucidate the correlation between molecular alterations and neuronal activity both within these 
regions, and in relation to the NAcSh.  
Last but not least, there exists the fact that within this thesis there existed a lack of 
significant differences between the VAirVPBS control and L2000-CBD treatment groups on the 
molecular level which did not correlate with differences observed in behavioral assays. While 
this may appear as an obstacle in understanding the observed EE-potentiated anxiolysis on the 
behavioral level, this interesting phenomenon can be explained by unique molecular interactions 
outside of the scope of this thesis investigation as well as the possibility that there may exist 
unique molecular profiles exhibited in other mesocorticolimbic associated regions (such as the 
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amygdala, hippocampus) induced by L2000-CBD treatment that are different in nature when 
compared to VAirVPBS treatments. Subsequently, these differences in molecular profiles may be 
associated with unique modulations of neuronal activity within the mesocorticolimbic system 
that can help elucidate the contrasting degrees of anxiolysis observed following the two 
treatment administrations. 
Nonetheless, despite these mysteries which remain unanswered and the endless molecular 
interactions which potentially underlie the observed molecular profiles following treatment 
administration, this exploratory thesis ultimately establishes a case for the presence of the 
entourage effect between cannabidiol and linalool that augments their collective anxiolytic 
potential. 
Conclusions and Future Directions 
 As mainstream adoption of cannabis and cannabis-related products grow, there exists a 
growing need for information surrounding the properties and associated mechanisms of cannabis 
to ensure safe usage, whether recreational or medicinal. Furthermore, recent advances in the past 
two decades regarding cannabis research has characterized the existence of various 
phytocannabinoids such as CBD and THC, as well as a multitude of terpenes which have 
demonstrated therapeutic properties when administered in an isolated manner. Increasingly 
however, explorations are being made in the field regarding combinatorial formulations of 
phytocannabinoid-phytocannabinoid and the potential for a superior therapeutic effect not 
elicited by either component substance alone; this effect, known as the Entourage Effect, has yet 
to be thoroughly explored in regard to phytocannabinoid-terpene formulations. 
 This thesis explored the potential presence of an Entourage Effect between linalool and 
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cannabidiol, demonstrating for the first time using behavioral assays that a combinatorial 
administration of these two compounds can yield EE-potentiated bright-space and fear-memory 
induced anxiolysis in acute treatment and chronic stress settings, as well as a significant 
reduction in open-space anxiety within specific contexts. In addition, this Entourage Effect was 
found to be critically modulated by GABAAR regulation and ERK activation, highlighting two 
potential mechanisms underlying the observed EE-potentiated anxiolysis following concurrent 
administration of odorous 2000 μL linalool and intra-NAcSh 5 ng/0.5μL cannabidiol treatment. 
While the lower dosage combination treatment involving 200 μL linalool and 5 ng/0.5μL 
cannabidiol resulted in some instances of EE-potentiated anxiolysis, the presence of the 
Entourage Effect was not as consistent as the higher linalool dosage combinatorial treatment; in 
conjunction with the absence of significant differences between these two treatments, dose-
dependent effects cannot be concluded at this time.  
Observations of molecular profiles demonstrated differential activations of GSK3β, Akt, 
ERK and JNK across treatment groups when standardized against control group expression 
levels. While the lack of significant differences in protein expression between VAirVPBS and 
L2000-CBD groups strongly suggests there exists other associated proteins and brain regions 
involved in characterizing the molecular profile elicited following L2000-CBD exposure, the 
preliminary findings of this thesis suggest that the EE-potentiated anxiolysis exhibited by this 
treatment group involves a unique interaction between the studied proteins and their associated 
pathways not observed in either component group alone. 
Although questions ultimately remain regarding the underlying mechanisms of the 
observed EE-potentiated anxiolysis induced by L2000-CBD treatment, the establishment of the 
Entourage Effect between the two compounds and their associated dosages opens up a new 
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chapter in the therapeutic potential of cannabis and cannabis-related products—as in addition to 
linalool, there exists several more terpenes with anxiolytic profiles theorized to yield EE-
potentiated effects that have yet to be explored. Given the relatively safe profile of these natural 
compounds when compared to conventional medications and their associated side effects, these 
natural medicines present a potential complimentary treatment, or even replacement in the 
treatment of anxiety and anxiety-related disorders. Furthermore, this thesis helps support 
emerging evidence suggesting that the NAcSh plays an integral role in affective memory 
formation and processing, thus giving greater credence to the brain region as a potential target 
for treatments towards mood disorders. Thus, while future investigations involving 
electrophysiological analysis, disconnection studies and associated brain regions in the 
mesocorticolimbic pathway are required to further substantiate any correlations between 
molecular and behavioral observations, this thesis nonetheless demonstrates the untapped 
therapeutic potential of cannabis—effectively laying the groundwork for future innovations in 
cannabis-related medical alternatives. 
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